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8ABSTRACT
Characteristic features in asthma and chronic obstructive pulmonary disease (COPD) are 
airfl ow limitation and bronchial infl ammation. During airway infl ammation, increased 
numbers of activated cells (e.g. eosinophils and neutrophils) associated with infl ammation 
are found in bronchial mucosa, in bronchoalveolar lavage (BAL) fl uid, in sputum, and, in 
severe cases, in blood. Both eosinophils and neutrophils contain various mediators in their 
intracellular granules. When such cells are activated, various types of harmful mediator 
are released into the immediate environment.
Until recently, investigation of airway infl ammation has mainly relied on monitoring of 
lung function. However, numerous bronchial biopsy and BAL fl uid studies have revealed 
that airway infl ammation can occur in the absence of bronchial hyper-reactivity, if respi-
ratory disease is mild or clinically well controlled. Cellular and biochemical accompani-
ments of airway infl ammation have been widely studied by investigation of BAL fl uid and 
bronchial biopsy samples. However, the invasiveness, inconvenience and risks of the pro-
cedures concerned have limited their use. It has been suggested that induction of sputum 
production constitutes a non-invasive safe way of investigating airway infl ammation.
The main aim of the studies described here was to improve detection and diagnosis of 
airway infl ammation in various respiratory disorders. In seeking to achieve this aim, results 
of lung-function tests and fi ndings relating to laboratory parameters were compared and 
sensitivities were determined in various groups of patients, especially in patients with 
early asthma. Other aims of the studies were to simplify means of inducing sputum pro-
duction and to investigate sputum-processing procedures, with a view to improving the 
clinical utility of the methods. Effects of treatment on markers of infl ammation were eva-
luated. The feasibility of inducing sputum production in children was also examined. 
Since data concerning the cell-specifi cities of markers of infl ammation were confl icting, 
the specifi cities of some granulocyte markers were studied at cellular level, using immuno-
cytochemical staining. Various fi xation and permeabilization methods were used in immu-
nocytochemical studies to determine the optimal procedure for detecting intracellular 
markers in situ.
Eosinophil peroxidase (EPO) and human neutrophil lipocalin (HNL) can be used as mar-
kers for identifi cation of eosinophils and neutrophils in sputum samples and BAL fl uid. 
Eosinophil cationic protein (ECP), widely employed as a marker, is not eosinophil-specifi c. 
It can be detected, by means of immunocytochemical methods, in both eosinophils and 
neutrophils. Fixation and permeabilization using the commercial reagent Ortho Permeafi x 
is the best means of detection of antigens in cells in sputum samples and BAL fl uid. Use 
of the currently recommended method of fi xation, involving an organic solvent, is inap-
propriate in this connection. 
Sputum production can be safely induced in patients suffering from respiratory disorders 
and healthy individuals through use of a low-output nebulizer. Use of a simplifi ed assay 
method for measuring levels of total granulocyte markers in sputum allows differentia-
tion between patients with respiratory disorders and healthy individuals. Determination 
of levels of total markers using this simplifi ed assay method gives results similar to those 
obtained through use of established assay methods for released markers. The results sug-
9gest that the assay method could be used in clinical practice to determine total marker 
levels in induced sputum samples.
Treatment of early mild asthma with an inhaled steroid is effective and worthwhile. Detec-
tion of the disease remains problematic, however, since both lung-function and bioche-
mical tests have low sensitivities. Sputum assays are a useful supplement to conventional 
lung-function testing. 
Key words: asthma, bronchoalveolar lavage (BAL), chronic obstructive pulmonary disease 
(COPD), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), human neut-
rophil lipocalin (HNL), induced sputum, intracellular marker, myeloperoxidase (MPO), 
sensitivity, specifi city
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1. INTRODUCTION
There is a great need to extend the means of detection of airway infl ammation in various 
respiratory disorders like asthma and chronic obstructive pulmonary disorder (COPD). 
Although lung-function tests remain the mainstay of diagnosis, they are insensitive in 
detecting early-stage infl ammation. According to an estimate of the Finnish National 
Asthma Programme, roughly 10% of the population other than asthma patients occasio-
nally exhibit symptoms suggestive of mild asthma, although results of lung-function tests 
remain normal or almost normal. The importance of early initiation of anti-infl ammatory 
medication for good treatment response and prevention of asthma chronicity has been 
emphasized. A means confi rming the existence of airway infl ammation in the absence of 
persistent pulmonary dysfunction is desirable.
Recent data indicate that induced sputum samples can be analysed to assess airway infl am-
mation. Sputum induction is less invasive than bronchoalveolar lavage (BAL) or bronchos-
copy. It has also been shown to be a safe and reliable way of investigating airway infl am-
mation. Sputum contains infl ammatory cells and innumerable markers. Induced sputum 
samples have increasingly been used to monitor airway infl ammation in various respiratory 
diseases, but complicated and time-consuming methods of handling them have limited 
their use. A simplifi ed procedure is needed to improve the clinical applicability of analysis 
of induced sputum samples. In epidemiology and other situations in which large popula-
tions need to be investigated a better procedure is also desirable. 
The main aim of the studies described here was to improve detection and diagnosis of 
airway infl ammation in various respiratory disorders. In seeking to achieve this aim, results 
of lung-function tests and relating to laboratory parameters were compared, and sensiti-
vities were determined in different groups of patient, especially in patients with early 
asthma. Another aim was to simplify means of sputum induction and to validate proces-
sing in order to improve the clinical utility of sputum induction. The effect of treatment 
on infl ammation markers was evaluated. The feasibility of sputum induction in children 
was also tested. Since there were confl icting data concerning the cell-specifi city of infl am-
mation markers, the specifi city of a number of granulocyte markers was studied at cellular 
level, using immunocytochemical staining. Different fi xation and permeabilization met-
hods were used in immunocytochemical studies to determine the optimal procedure for 
detecting intracellular markers in situ. 
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2.REVIEW OF THE LITERATURE
2.1. Airway infl ammation in asthma and chronic obstructive 
        pulmonary disease 
Asthma is tending to become commoner and less severe in Finland. It currently affects 
over 100 million people worldwide [57]. All age groups and all races suffer. Asthma is 
currently defi ned as a chronic infl ammatory disorder of the airways, marked by increases in 
numbers of cells associated with infl ammation, such as mast cells and eosinophils [135]. 
Clinically, airway infl ammation causes symptoms that include varying degree of obstruc-
tion of the bronchi that are at least partly reversible, spontaneously or with treatment. 
Infl ammation also increases airway responsiveness to many irritants. Recurring eosinophi-
lic airway infl ammation may affect more individuals than those diagnosed as asthmatic. 
The Finnish Asthma Programme [134] estimated that 5% of the Finnish population suffer 
from asthma but another 10% experience occasional asthma-like symptoms. Bronchial 
infl ammation is found in patients with newly detected or mild intermittent asthma [109, 
199], and in some patients with chronic cough but normal lung function [16, 49, 50]. It 
has been argued that, at the time asthma is diagnosed, detection of airway infl ammation 
is often late [171].
The American Thoracic Society has defi ned chronic obstructive pulmonary disease (COPD) 
as a disorder characterized by abnormal results in tests of expiratory fl ow that do not 
change markedly over periods of several months [4]. Three disorders are involved in 
COPD, emphysema, peripheral airway disease and chronic bronchitis. Emphysema is 
defi ned as a condition of the lung characterized by abnormal permanent enlargement of air 
spaces distal to terminal bronchioles. The term peripheral airway disease covers a variety of 
morphological abnormalities that can precede development of emphysema. Chronic bron-
chitis has been defi ned clinically as a condition in which cough and excessive mucus sec-
retion occur most days for at least three months of the year over at least two successive 
years. An individual patient can be affected by from one to three of these conditions.
Although airfl ow impairment and bronchial infl ammation are both found in asthma and 
COPD, diagnosis has until recent years been based on symptom history and results of pul-
monary function tests. The presence of activated cells (e.g. eosinophils and neutrophils) 
and structural changes in the bronchial mucosa characteristically accompany infl amma-
tion. In asthma, eosinophils are considered to be the effector cells, the contribution of 
neutrophils is unclear. Increased numbers of neutrophils are present in airways in patients 
with COPD as well as in patients with respiratory infections or exacerbations of asthma 
[37, 89, 145,190]. Both eosinophils and neutrophils contain in their intracellular granu-
les several mediators, which are released by various stimuli. Infl ammatory changes were 
fi rst studied with the help of airway biopsies and bronchoalveolar lavage fl uid samples but 
subsequently have been increasingly investigated via sputum samples [17, 37, 48, 64, 72, 
109,151, 155]. 
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2.2. Infl ammatory cells and infl ammatory-cell markers  
        in sputum
Several cell types have been characteristically found in infl ammatory infi ltrates from air-
ways in asthma, COPD and other respiratory conditions. Sputum cells can be divided into 
those that have exfoliated from the bronchial mucosa and alveolar areas, and infl amma-
tory cells that have appeared in response to specifi c stimuli. The infl ammatory cells are all 
representatives of the reticuloendothelial system, which function primarily as phagocytes, 
elements of the immune defence mechanism or both. The cells include eosinophils, neut-
rophils, mast cells, lymphocytes and macrophages. When the cells are activated, various 
types of protein, which are harmful, are released, together with regulatory cytokines. They 
cause infl ammation in the airway and affect its intensity. 
2.2.1. Eosinophils
Eosinophilic granulocytes are so named because they are stained intensely by eosin. Under 
the light microscope, a bi-lobed nucleus is typically seen in a normal healthy eosinophil. 
A prominent feature of the eosinophil is the presence of many spherical or ovoid granules 
in their cytoplasm [54]. Four distinct population of granule (primary granules, secondary 
or specifi c granules, small granules, lipid bodies) have been recognized (Fig. 1).
Figure 1. A human eosinophil with the typical bi-lobed nucleus and the four main gra-
nules. Adapted from Giembycz and Lindsay [52].
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Eosinophils are involved in defence against parasites but are best known for their role in 
allergic diseases and asthma [33]. High numbers of eosinophils occur in the blood during 
parasite infections, and in various allergic conditions if the latter are severe. High num-
bers of eosinophils are more readily demonstrable in local body fl uids and tissues [155]. In 
biopsy specimens from patients with symptomatic asthma, eosinophils are found in high 
numbers in the airway epithelium and in deeper bronchial tissues [109]. Bronchial eosi-
nophilia is not unique to asthma. Eosinophils can often be seen in biopsy specimens from 
patients with chronic bronchitis and COPD. However, numbers are usually lower than 
in patients with asthma [107]. The proportion of eosinophils in sputum is a more sensi-
tive marker of asthmatic airway infl ammation than the proportion of eosinophils in blood 
[155]. Numbers of eosinophils are also high in nasal mucous in patients with perennial 
allergic and non-allergic rhinitis [5]. Numbers of eosinophils are also high in conjunctival 
biopsy specimens taken after allergen challenge [8].
Table 1. Substances secreted by eosinophils. Adapted from [52].
Class and substance Granule (location) 
    Granule basic proteins
     Eosinophil cationic protein (ECP)                 Secondary (matrix), small (matrix)
     Eosinophil peroxidase (EPO)                         Secondary (matrix), lipid bodies
     Eosinophil protein X (EPX)                          Secondary (matrix)
     Major basic protein (MBP)                            Secondary (core, matrix)
     Charcot-Leyden crystals (CLC)                      Primary
    Cytokines
     Interleukin-2, -4 and -5                               Secondary (core)
     Interleukin-6                                                Secondary (matrix)
     Tumour necrosis factor-α (TNF-α)                Secondary (matrix)
     Granulocyte-macrophage colony-stimulating factor (GM-CSF)  Secondary (core)
     Macrophage migration inhibitory factor (MIF)                  
    Chemokines
     RANTES                                                      Secondary
     Eotaxin                                                         
    Growth factors
     Transforming growth factor-α and -β (TGF-α, TGF-β)    
    Enzymes
     β-Glucuronidase                                           Secondary (core, matrix)
     Lysozyme                                                      Secondary (matrix)
     Elastase                                                         Secondary, small
     Catalase                                                         Small
     Acid phosphatase                                          Small
     Arylsulphatase B                                           Small
    Lipid mediators
     Cysteinyl leukotrienes LTC
4
, LTD
4
 and LTE
4
     Platelet activation factor (PAF)                     
     Cyclooxygenase (COX)                                  
     5-Lipoxygenase (5-LO)                                         
     Oxygen radicals (due to activation of NADPH oxidase)
      H
2
O
2
, O
2
-, OH.                                                      
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Eosinophil granules contain several proteins, which are secreted into the extracellular envi-
ronment following stimulation. They include basic proteins, cytokines, chemokines, lipid 
mediators and oxygen radicals (Table 1). 
Charcot-Leyden crystal (CLC) protein (or lysophospholipase) makes up to 10% of the total 
protein in eosinophils. Its function is unknown, although it has been speculated that CLC 
may protect eosinophils from the toxic effects of lysophospholipids. The most distinguis-
hing feature of the eosinophils is its high content of highly charged cationic proteins, eosi-
nophil cationic protein (ECP), eosinophil protein X (EPX) and major basic protein (MBP). 
These proteins together with eosinophil peroxidase (EPO) have been implicated as fi nal 
effector molecules in eosinophil-mediated tissue damage. All these proteins are shown to 
be highly toxic to cells of the respiratory epithelium [56].
Mechanisms leading to eosinophil degranulation are not well understood. At least three 
discrete processes have been defi ned that result in the release of granule contents from 
eosinophils: secretion, piecemeal degranulation and cytolysis (necrosis) [52]. Secretion is 
an exocytotic process involving the fusion of granules with the plasma membrane and the 
partial or total extrusion of secretory products. In piecemeal degranulation, small protein-
containing vesicles bud off from the secondary granules. The granules are gradually emp-
tyed. In cytolysis the clusters of free eosinophil granules are released into surrounding 
structures. Results of earlier studies suggested that release of granule proteins depends on 
the stimulus to which the cells are exposed [20, 92,191]. Release of ECP and EPO has 
been observed to differ depending on whether eosinophils were stimulation via receptors 
for immunoglobulin G (IgG) or immunoglobulin E (IgE). Secretion of EPO was by an 
IgE-dependent mechanism [191]. Release of ECP was IgG-dependent [191]. High levels 
of serum ECP but not of serum EPO have been observed during the fi rst few days of acute 
bacterial infection [92].
Sensitive methods allow levels of these proteins to be measured in blood and most tissue 
fl uids. Most commonly, serum ECP levels are measured in asthma [197, 198] and atopic 
dermatitis [91]. EPX is excreted in the urine, in which it can be accurately measured. 
Urine has been analysed in evaluating airway infl ammation [34, 106, 116]. The procedure 
is obviously advantageous in relation to children because of its non-invasive nature.
2.2.2. Neutrophils
Neutrophil granulocytes or polymorphonuclear neutrophils are the rapid response cells 
of acute infl ammation and a major component of host defense. Activated neutrophils 
are toxic to other cells and can injure tissues. They account for 50 to 60% of all circu-
lating leukocytes and are believed to be largely responsible for the destructive processes 
and symptoms seen in various infl ammatory diseases. Despite their benefi cial role in host 
defence, neutrophils and their pro-infl ammatory products are increasingly implicated in 
the pathogenesis of acute and chronic infl ammatory diseases. 
Neutrophils are phagocytic. Within minutes of tissue damage or pathogen invasion, neut-
rophils pass through blood vessels with the aid of adhesion molecules by which they can 
adhere to endothelium. They migrate to the tissue involved, where they start to engulf and 
eliminate any infective material. Micro-organisms are killed by release of large numbers of 
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oxygen radicals and various granule proteins. Neutrophils appear to reside normally in the 
larger airways in both normal and hyper-responsive individuals. High numbers of neut-
rophils are not generally observed in bronchial biopsy material from non-severe asthmatics 
[109], but are present in patients with COPD, respiratory infection or asthma exacerba-
tion [4, 37]. Bronchoscopic studies in patients with chronic bronchitis and COPD have 
shown that neutrophil numbers are not high in bronchial mucosa but are signifi cantly 
increased in bronchoalveolar lavage (BAL) fl uid [107]. Neutrophil numbers are not merely 
high: the neutrophils are activated, as shown by high levels of myeloperoxidase (MPO) in 
BAL-fl uid [107]. Smokers with asthma have also been found to have high levels of MPO 
in BAL fl uid [14].
Table 2. The granules of human neutrophils and their contents. Adopted from [204].
 Location Protein Function 
 Azurophilic granule
  Myeloperoxidase (MPO) Microbicidal enzyme
  Lysozyme Microbicidal enzyme
  Defensins Microbicidal factor
  Elastase Neutral protease
  Cathepsin G Neutral protease
  Cathepsin B and D Lysosomal acid hydrolase
  β-Glucuronidase Lysosomal acid hydrolase
  Acid phosphatase Lysosomal acid hydrolase
 Specifi c granule
  Human neutrophil lipocalin (HNL) Miscellaneous
  Lysozyme Microbicidal enzyme
  Collagenase Neutral metalloproteinase
  Lactoferrin Miscellaneous
  Histaminase Miscellaneous
  Plasminogen activator Neutral protease
 Tertiary granule
  Gelatinase Neutral metalloproteinase
                Alkaline phosphatase                          Miscellaneous
Neutrophils are similar in size to eosinophils. Neutrophils also contain granules in their 
cytoplasm but unlike eosinophils, have from three to six lobes to their nuclei. On the 
basis of peroxidase staining, the cytoplasm of human neutrophils contains two types of 
granule, peroxidase-positive primary (synonyms: azurophilic, non-specifi c, basophilic) and 
peroxidase-negative secondary (synonyms: specifi c, eosinophilic, acidophilic, adhesomes) 
[204]. Specifi c granules are twice as numerous as azurophilic granules in mature neut-
rophils. Azurophilic granules contain mainly anti-microbial agents. The major role of spe-
cifi c granules is to provide an intracellular reserve of important membrane components 
(e.g. chemotaxin reseptors, adhesion molecules, components of the NADPH oxidase). A 
further type of granule, tertiary (synonyms: storage, gelatinase, secretory vesicles, C-par-
ticles) is also recognised [73, 204]. As granular proteins secreted are located in different 
cytoplasmic granules (Table 2), it has been suggested that the three types of granule are 
controlled by different factors [10]. Secondary granule proteins (e.g. human neutrophil 
lipocalin (HNL) are released much more readily, in response to much lower segretagogue 
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concentrations, than primary granules and their proteins (e.g. MPO) [10]. A number of 
different groups of receptors (for opsonised particles, chemotactic factors, cytokines, growh 
factors and adhesion moleculs) are found in neutrophil surface. Neutrophils are capable of 
producing a limited but important range of cytokines and chemokines (e.g. interleukin-1, 
IL-6, IL-8, TNF-α, GM-CSF) and thus controlling the infl ux of more neutrophils but also 
the migration of monocytes which will mature into infl ammatory macrophages [73, 204].
Sensitive immunoassay methods have been developed to measure levels of neutrophilic 
secretory proteins in blood and other body fl uids [94, 211]. Markers of neutrophil activa-
tion are elastase, lactoferrin, MPO and HNL, the last unique to neutrophils [178]. Elastase 
and MPO are also found in monocytes [93, 139]. Lysozyme is also secreted by monocytes 
and macrophages [198]. Many serous glands produce lactoferrin [164]. The clinical value 
of neutrophil markers is not yet clear. Results of HNL determinations have been used 
to distinguish between acute viral and bacterial infection [212], and may be better than 
determination of levels of C-reactive protein in this respect.
2.2.3. Mast cells/basophils
Human mast cells (tissue basophils) do not usually circulate in the blood. They are hete-
rogeneous and have a number of functions. The physiological role of mast cells is not well 
known. However, they play key parts in anaphylaxis and allergic reactions of the imme-
diate type. The secretory granule of a human mast cell contains a crystalline complex of 
infl ammatory mediators bound ionically to a proteoglycan matrix. When mast cells are 
activated, the secretory granules swell and lose their crystalline nature, as the mediator 
complex dissolves. Preformed and newly generated mediators such as histamine, tryptase, 
prostaglandin D
2
, leukotriene C
4
 and PAF are expelled into the environment of the cells 
[26]. The biological effects of mast-cell mediators include smooth-muscle contraction, 
development of mucosal oedema, nerve stimulation and glandular secretion [26].
Mast cells are found in the bronchial walls of both normal subjects and asthma patients 
[14]. In asthma, they are highly degranulated, as indicated by results of titration of 
mediators in BAL fl uid [14] and as shown by electron microscopy [108]. Tryptase accounts 
for a substantial percentage, perhaps 20, of total mast-cell protein [175]. Tryptase measu-
rement in both blood and tissue fl uids has been used to determine mast-cell activation. 
Tryptase is also found in basophils, at about 1% of the level in mast cells. Basophils are 
very rich in histamine; in fact, most histamine in blood originates from basophils [9]. In 
serum, high levels of tryptase have only been observed in systemic mast cell disorders, 
such as anaphylaxis [177] and mastocytosis [176]. In local body fl uids, high levels of tryp-
tase and histamine have been found in BAL fl uid in cases of allergic asthma, in sputum 
during asthma exacerbation, in nasal washings in cases of rhinitis, and in tear fl uid in 
patients with allergic conjunctivitis [14, 37, 121, 165]. 
2.2.4. Lymphocytes
Lymphocytes play important roles in the immune response. There are two physiologically 
and functionally distinct lymphocyte populations, T lymphocytes and B lymphocytes [167].
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Some lymphocytes are frequently present in sputum. It is diffi cult to differentiate mor-
phologically between T and B lymphocytes with a light microscope using conventional 
histochemical stains. However, T lymphocytes exist as into two subpopulations, CD8 and 
CD4, that can be distinguished by cell-surface markers, using fl ow-cytometric and immu-
nocytochemical techniques [100, 119]. In asthma, airway T lymphocytes are activated, as 
indicated by increased expression of the cell-surface markers CD25 (interleukin-2 recep-
tor) and HLA-DR [205]. CD8-positive T lymphocytes are more rarely identifi ed in the 
blood than CD4-positive T lymphocytes in exacerbations of asthma but there is no corre-
lation between asthma severity and numbers of CD4-positive T lymphocytes [32]. In a 
study by Kidney et al. [100], lymphocyte profi les in sputum were determined by means 
of fl ow cytometry. They noted that sputum from patients with asthma contained more B 
lymphocytes than sputum from non-asthmatic subjects. Numbers of B lymphocytes also 
correlated closely with numbers of eosinophils in sputum. At least two subsets of helper 
T cells (Th1 and Th2) secrete various cytokines on activation. Th2 cells mainly synthesize 
IL-3, IL-4, IL-5 and IL-10, whereas the cytokine profi le of Th1 cells includes IFN-γ, IL-2 
and GM-CSF [24]. The Th2 phenotype appears to predominate in bronchial biopsy and 
BAL fl uid samples from asthma patients [31, 166]. 
2.2.5. Macrophages/monocytes
Macrophages are the most numerous cells in airway infl ammatory infi ltrate. They account 
for 80 to 90% of airway cells in BAL fl uid [58]. The macrophage precursor is the blood 
monocyte, which matures and settles in tissues. Macrophages in airways represent a con-
tinuum of cells ranging from blood monocytes via transitional monocytic macrophages to 
fully activated macrophages. Macrophages are involved in the pathogenesis of asthma [15]. 
Results by the study by Chanez et al. [25] showed that alveolar macrophages from patients 
with asthma were less dense than those of normal subjects. Activation of macrophages has 
been found to correlate with asthma severity [29].
Macrophages have several important capabilities. As scavenger cells, a prime function is 
intracellular breakdown and disposal of phagocytosed particles and soluble material [144]. 
The role of macrophages in immune reactions is well documented. They process antigens 
and act as antigen-presenting cells [167]. It is now well established that macrophages act 
as infl ammatory cells through secretion of bronchoconstrictor prostaglandins, leukotrienes 
and oxygen radicals [112]. Alveolar macrophages produce a number of cytokines, inclu-
ding IL-1, IL-6, IL-8, IL-10, GM-CSF, TNF-α, interferon-γ and platelet-derived growth 
factor (PDGF) as well as upregulation of inducible nitric oxide synthase (iNOS) [98, 
111]. Airway macrophages may play a regulatory role, establishing immunological balance 
in the lungs, by stimulation or suppression of T-cells [188]. Functionally different and 
phenotypically distinct populations of macrophages have been demonstrated in the bron-
chial walls of healthy subjects, and in BAL fl uid and sputum samples [113, 162]. 
Macrophages in induced sputum samples are maturing or mature [113]. Monocytes are 
seldom found in sputum.
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2.3. Obtaining and processing sputum samples
The obvious target for study of airway infl ammation is the bronchial mucosa. Suitable 
materials for study are biopsy samples, BAL fl uid and sputum samples. Blood or serum 
can also be used but infl ammation has to be fairly severe [168, 197, 198]. Invasive pro-
cedures are necessary to obtain biopsy samples and BAL fl uid. The discomfort, incon-
venience and risks of biopsy and BAL have limited their use. During the last decade, a 
non-invasive method has been developed in which sputum samples are used to investi-
gate infl ammatory cells, soluble proteins and messenger RNA from the lower airways 
[17, 37, 48, 64, 72, 151, 155]. It has been suggested in recent publications that exa-
mination of sputum samples has many advantages over the more invasive methods. 
Production of large amounts of sputum by a patient in itself indicates that disease is 
present.
In Finland, the routine method of diagnosis of tuberculosis has been to collect sponta-
neous sputum samples on three successive mornings and to identify Mycobacterium tuber-
culosis after staining. The method remains valid [136, 217]. Sputum is produced spon-
taneously by most but not all asthmatics, and by COPD patients, but not by healthy 
individuals. Inability to produce sputum spontaneously can be overcome by inducting 
its production through inhalation of hypertonic saline. Sputum induction was initially 
developed in connection with investigation of lung cancer and respiratory infections. 
It has been used, for example, in diagnosing Pneumocystis carinii infections in human-
immunodefi ciency-virus-positive patients [104]. The method was subsequently modi-
fi ed for use in asthmatics and those suffering from other respiratory conditions. 
2.3.1. Composition of sputum
Sputum can be divided into cellular, non-cellular and non-pulmonary constituents. The 
cellular constituent can roughly be divided into cells exfoliated from the bronchial mucosa 
and alveolar areas, and infl ammatory cells from the circulation. The non-cellular constitu-
ent originates from the mucus-producing cells of the lung, non-cellular exudate or tran-
sudate (e.g. albumin, transferrin) and cell breakdown products (e.g. DNA fi bres, Charcot-
Leyden crystals, Curschmann’s spirals). Non-pulmonary elements include micro-organisms 
(e.g. Mycobacterium tuberculosis) and inhaled or aspirated material (e.g. saline). Investigation 
of the chemical composition of sputum is complicated because it is a variable mixture 
of tracheobronchial secretions, exudate and transudate from infl ammatory processes and 
saliva.
2.3.2. Sputum induction
Although sputum induction has been extensively used during the last 10 years, the 
infl uence of technical factors on its practicability and reproducibility has been little stu-
died. Sputum induction is infl uenced not only by technical factors such as nebulizer 
output, saline concentration, particle size of nebulized saline and pre-treatment, but by 
non-technical factors, such as whether the subject smokes, and disease severity. The lack 
of any standard relating to induction makes it diffi cult to evaluate the infl uence of these 
factors on amount of sputum produced and reproducibility of sputum production, espe-
cially as regards comparison of results from different laboratories.
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Inhalation of isotonic or hypertonic solutions delivered by a nebulizer has been shown 
to induce small amounts of airway secretion that can be expectorated and analysed. The 
mechanisms by which induction of airway secretion occurs are not fully understood. At 
least four have been suggested. They are (1) a volume effect, (2) an increase in mucoci-
liary clearance, (3) an osmotic effect, and (4) stimulation of glandular secretions [160]. 
A volume effect can probably be excluded because inhalation of isotonic saline is less 
effective than inhalation of hypertonic saline [160]. Mucous clearance, primarily cont-
rolled by ciliary beating and the cough mechanism, has been shown to be increased by 
inhalation of hypertonic saline in patients with chronic bronchitis and cystic fi brosis 
[142]. However, the increased clearance has not been entirely accounted for by increased 
cough. Inhalation of saline increases the osmolality of the airway lining fl uid, leading 
to increased vascular permeability in the bronchial mucosa. In vivo instillation of hyper-
tonic solution into the airways has shown that levels of albumin and other markers of 
increased vascular permeability in bronchial lavage fl uid are not increased in the airways 
[42, 60]. 
Umeno et al. [193] showed that hypertonic saline inhalation causes infl ammation in the 
trachea of rats via release of tachykinins from nerve cells. Although no such mechanism 
has been demonstrated in man, other mediators could also be released after inhalation of 
hypertonic saline [60]. In evaluating levels of soluble markers in induced sputum samp-
les, it may therefore be diffi cult to decide whether they existed in the airways or were 
released because of hypertonic saline inhalation. It has been suggested that albumin and 
fi brinogen can be released in this way [39].
2.3.3. Concentration of saline
The concentrations of saline used for sputum induction have ranged from isotonic (0.9% 
NaCl) to 7%. Some investigators vary concentration during the procedure, starting with 
3% and increasing to 4 or 5% [7, 16, 151, 158]. Others keep the concentration of the 
saline constant [38, 170, 194]. Whether increasing saline concentration during induction 
is better than keeping the concentration constant has not so far been proved. Sputum 
induction has been found to be more successful when hypertonic saline has been used (3%, 
or 3 to 5% sequentially) than when isotonic saline has been used [160]. There is no dif-
ference in the cell composition of sputum induced by isotonic or hypertonic saline inha-
lation but contamination with saliva was greatest in isotonic saline-induced sputum [7]. 
Hypertonic saline has also been found to increase bronchial responsiveness to methacho-
line in asthmatics. Isotonic saline did not have this effect [7].
2.3.4. Nebulizer
Various types of nebulizer have been used to induce sputum [7, 16, 38, 76, 151]. The type 
and output of the nebulizer signifi cantly affect the success rate of sputum induction. It is 
generally believed that a high output, often more than one to two millilitres per minute, 
is required for a high success rate. Accordingly, ultrasonic nebulizers are preferred. In a 
study by Popov et al. [160], a jet nebulizer (Pari LL) was compared with two ultrasonic 
nebulizers (De Vilbiss Ultraneb 99 and Fisoneb). The ultrasonic nebulizers were better 
than the jet nebulizer in inducing sputum production, as indicated by countable cytos-
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pins, weight of sputum and total cell counts [160]. In other studies ultrasonic nebulizers 
with lower outputs have been used and no signifi cant differences in the variables mentio-
ned have been found. The amount of solution that needs to be inhaled to induce produc-
tion of a suffi cient amount of sputum is unknown.
Hyper- and hypotonic droplets of the same initial size can be deposited in different regio-
nal patterns (Fig. 2) [149]. Hypertonic aerosols absorb water vapour from humid envi-
ronments until droplet vapour pressure is in equilibrium with the vapour pressure of the 
surroundings, or until they are deposited. If airway fl uid is isotonic, equilibrium will be 
reached when droplets have absorbed enough water to become isotonic themselves. In 
doing so, they will increase in size. In the case of hypotonic droplets equilibrium is pre-
sumably reached once they have lost enough water to become isotonic and, consequently, 
decreased in size. The size of an inhaled particle will affect its deposition with the airway 
(upper vs. lower). This, in turn, could affect success of sputum induction. 
Figure 2. Representation of hygroscopic growth and shrinkage to equilibrium size. 
Adapted from [149].
2.3.5. Duration and frequency of induction 
The duration of inhalation and whether it is repeated are important variables in relation 
to sputum induction. Fahy et al. [39] reported no change in sputum composition 20 hours 
after previous induction, although in asthmatic subjects the range of percentage of neut-
rophils widened. This has also been observed in healthy subjects [138]. Holz et al. [76] 
demonstrated marked increases in neutrophil counts and ECP concentrations in induced 
sputum 24 hours after previous sputum induction in healthy and mildly asthmatic sub-
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jects. In contrast, numbers of other cell types, including eosinophils, did not alter. The 
result highlights a need for care when drawing conclusions following repeated sputum 
testing.
In at least two studies it has been found that cellular and biochemical constituents of 
induced sputum change during the course of sputum induction [46, 75]. Gershman et 
al. [46] noted that neutrophils and eosinophils prominent in samples collected early on 
during sputum induction whereas lymphocytes and macrophages prominent in samples 
collected later. In addition, mucin concentrations, unlike surfactant concentrations, were 
higher in samples collected early on inhalation during inhalation (after zero to four minu-
tes) than in samples collected later (after 16 to 20 minutes of inhalation). It has been 
suggested that consecutive sputum samples obtained during a single induction procedure 
refl ect conditions at different lung depths, i.e. that central airways are sampled early, 
peripheral airways and alveoli later [46, 75]. Some authors have suggested discarding the 
fi rst sample and collecting and analysing only subsequent samples [86].
No studies concerning maximum acceptable duration of induction have been published. 
There has to be a compromise between success and safety. In some earlier studies induc-
tion was stopped once an adequate sample had been obtained. This approach is no longer 
regarded as acceptable for research purposes. However, short inhalation times (e.g. 15 to 
20 minutes) seems to be as successful and practicable as long inhalation times (e.g. 30 
minutes). Data from recent studies highlight the need to standardize duration of sputum 
induction. 
2.3.6. Spontaneous versus induced sputum
Some patients with asthma and COPD, particularly those suffering an acute exacerbation 
or with severe symptoms, can produce sputum spontaneously. Concerns have been raised 
that inhalation of hypertonic saline could in itself alter cell or marker contents and con-
centrations in sputum. Spontaneous sputum samples have been shown to contain percen-
tages of infl ammatory cells and mediators similar to those in induced sputum samples [11, 
157]. Cell viability was signifi cantly higher in induced sputum samples than in sponta-
neous sputum samples but there were no signifi cant differences in total or differential cell 
counts [11]. Quality of cell samples was also poorer in relation to morphology in sponta-
neous sputum samples than in induced sputum samples. Prolonged residence of mucus 
secretion in an airway could lead to fewer viable cells and less easy distinction between 
different types of infl ammatory cells. Sputum induction could also result in mobilization 
of a newer cell population after an older. Perhaps dying population of cells has been spon-
taneously expectorated [157]. In this respect, induced sputum samples would be prefe-
rable to spontaneous sputum samples.
2.3.7. Safety of sputum induction
Hypertonic saline inhalation can cause bronchoconstriction in asthmatic subjects [7, 179]. 
The mechanism of the effect is unknown but may involve activation of airway mast cells 
or sensory nerve endings [60, 122]. Most investigators use a short-acting β
2
-agonist to 
prevent excessive bronchoconstriction in asthmatic and COPD subjects in whom sputum 
is induced [95, 151, 194] but some do not [7, 49, 81]. Typically, a 200 to 400-µg dose 
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of salbutamol representing two to four puffs from a metered dose inhaler, is used. Pre-
treatment of this kind is not universally effective in preventing hypertonic saline-induced 
bronchoconstriction, however. Despite pre-treatment with an inhaled β
2
-agonist, falls in 
forced expiratory volume in one second (FEV
1
) of greater that 20% have been reported in 
patients with asthma and COPD [44, 170].
Monitoring of pulmonary function is necessary for safety reasons, to allow bronchoconstric-
tion to be prevented or detected. No standard approach to pulmonary-function monito-
ring during sputum induction has been agreed but many investigators measure pulmonary 
function every fi ve to 10 minutes, and every time symptoms occur [151, 170]. Some have 
suggested that pulmonary function should fi rst be measured within one minute of start 
commencement of sputum induction to detect subjects particularly sensitive to hypertonic 
saline inhalation. Different methods have been used. Most investigators have employed 
spirometers [151, 170] but some have used peak-fl ow meters (PEF) [207]. 
2.3.8. Sputum processing
Sputum contains secretions produced by gland cells of the respiratory epithelium and sub-
mucosa, as well as infl ammatory cells that have migrated from the blood stream. In addi-
tion to sputum proper, induced sputum contains saliva, transudate and inhaled sodium 
chloride solution. All of these factors infl uence sputum concentration. Methods used to 
handle before biochemical and cellular analysis have varied and are under development 
[38, 72, 81, 97, 103, 152, 153]. In consequence, information from different studies cannot 
be precisely interpreted and compared. Techniques used in handling specimens during and 
after collection are as important as the methods used for collection.
2.3.9. Whole sputum samples versus sputum plugs
A major methodological decision that will affect results is whether to use an entire sample, 
including saliva and contamination, or only parts of the sample (sputum plugs). The fi rst 
approach involves processing the entire expectorate, consisting of sputum and saliva [38]. 
The second approach involves selecting all viscid or dense portions from the expectorated 
sample with the aid of forceps and an inverted microscope [71]. To reduce salivary conta-
mination, saliva and sputum can be collected separately [47, 154]. Both methods have 
advantages and disadvantages. 
The advantage of using only sputum plugs is that squamous epithelial cell contamination 
is normally less than 5% [154] (ERS Sputum Task Force, P Rytilä, personal communica-
tion). This makes cell counting easier and more rapid. Concentrations of markers in the 
fl uid phase are relatively unaffected by saliva, and correction for dilution can be more 
accurate. A disadvantage is that selection of sputum plugs using an inverted microscope 
and forceps is diffi cult and therefore takes time. Plugs can be few or absent, a situation 
common in patients receiving proper treatment.
Using entire expectorate is quicker than selecting sputum plugs. Entire expectorate is 
a mixture of sputum and saliva in unknown and indeterminable proportions. The saliva 
dilutes the sputum and affects fl uid-phase measurements. The presence of squamous cells, 
which, together with true sputum cells, become enriched during cell separation, affects 
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differential cell counts. Up to 50% of cells on microscope slides can be squamous cells. 
This effect can be partly avoided by fi ltering samples before making cytospin preparations. 
However, separation is always incomplete. Slight reductions in total cell counts have been 
observed [36]. Data on whether or not differential cell counts obtained using these two 
methods differ are inconsistent. 
2.3.10. Homogenization
Sputum should be processed as soon as possible, within two hours if cell counts and stai-
ning are to be optimal [101]. Complete homogenization is a prerequisite if cell counts 
are to be reliable. Homogenization of sputum using enzymes (e.g. trypsin [23, 148] and 
pancreatin [30]) and some chemical agent (e.g. hydrochloric acid [187]) has been tried 
in connection with diagnosis of pulmonary malignancies. However, the agents mentioned 
can affect the cell morphology. On the whole the methods are tedious and have not been 
widely employed. 
Homogenization can be achieved through use of dithiothreitol (DTT) or dithioerythritol 
(DTE). DTE is an optical isomer of DTT and has similar effects. DTT and DTE are muco-
lytic agents which act by reducing the disulphide bonds present in mucus [28, 66]. The 
disulphide bonds are formed between two cysteine amino acids. DTT (DTE) can affect 
disulphide bonds present in a number of proteins (e.g. mediators, imfl ammatory markers). 
In addition to affecting disulphide bonds in these proteins, DTT can also interfere with 
disulphide bonds in immunoassay capture antibodies, disrupting them and reducing assay 
sensitivity. Use of DTT (DTE) has been shown to be more effective in dispersing cells 
than addition of saline or buffer alone [35]. Microbiologists have used DTT to liquefy 
sputum in concentrating Pneumocystis carinii and other organisms [64, 215]. Wooten and 
Dulfano [208] saw no alteration in cell morphology after careful examination of Papa-
nicolaou smears of DTT-treated and untreated samples from the same specimen. They 
noted that characteristic differences between various cell types were preserved. However 
the emphasis of this work was on infl ammatory cell counts. 
There is no fi xed duration and temperature for homogenization in processing sputum. 
Times mentioned in publications have varied from 10 to 30 minutes [43, 95, 153], tem-
peratures from +4°C to +37°C [43, 95, 114]. Different exposure times to DTT (0.1%) 
at room temperature have been shown to have no effect on differential cell counts [161]. 
Louis et al. [114] treated sputum samples with DTE. Their results show that DTE did 
not induce release of ECP or histamine with processing of sputum at room temperature or 
+37°C. The fi nding suggests that processing at +37°C may be of no benefi t in comparison 
with processing at room temperature. The effects of temperature on mediators have not 
been fully investigated but temperature appears not to infl uence ECP, EPX, EPO or MPO 
levels [62, 98, 114].
Physical methods of homogenization, use of saline, ultracentrifugation, glass homogeniza-
tion or ultrasonication, have been tried [62, 102, 103, 114, 174, 184]. Use of saline alone 
resulted in incomplete dispersion of cells [114]. In a study by Stockley [184], a sputum 
“sol” phase was obtained by ultracentrifugation. Results of enzyme assays for MPO, IL-8 
and leukotriene B
4
 were found to be reproducible but recovery was poor in the case of 
MPO. Several cytokines have been determined in sputum homogenized with a glass homo-
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genizer for 15 minutes at +4°C. The recovery rate exceeded 75% of the added cytokine 
[103]. Ultrasonifi cation disrupts cells and releases intracellular mediators [62]. To date 
none of above-mentioned methods have been widely used.
2.3.11. Sputum for immunocytochemical studies
Sputum samples are frequently collected into vessels containing 70% ethanol, especially if 
information is needed about cell morphology in malignancy studies. However, this appro-
ach has not been adopted in sputum studies since an ethanol-fi xation procedure prevents 
assay for biochemical markers. For immunocytochemical staining, induced sputum is fi rst 
homogenized, then samples are taken and cytocentrifuged. Conventionally, a cytocentri-
fuged sample is treated with acetone or alcohol, e.g. methanol, prior to incubation with 
a primary antibody. The commonest approach in sputum studies has been to treat cells 
with periodate-lysine-paraformaldehyde (PLP) or organic solvents [43, 53, 113, 144, 161]. 
Paraformaldehyde (PFA) in combination with a mild non-ionic saponin has been used in 
biopsy studies [192] and has also been adopted for use in sputum studies [53].
Flow cytometric analysis of BAL cells has been used in the study of interstitial disease and 
asthma. Few reports have been published of investigations in which this technique has 
been used for studying cell-surface markers in sputum [64]. If T-lymphocyte subsets are 
being studied, not all samples are suitable for fl ow cytometric analysis because numbers 
of lymphocytes in sputum are low. Filtration of samples is necessary to remove cellular 
debris. This leads to some loss of cells. Mucolytic agents used to homogenize sputum can 
affect detection of surface markers.
2.4. Studying airway infl ammation by means of sputum
        examination
Examination of sputum for indices of airway infl ammation is not new. More than 100 
years ago, Gollasch observed increases in numbers of eosinophils in the sputum of asthma-
tics [59]. In 1958 Bickerman et al. [12] were the fi rst to report analysis of sputum, pro-
duction of which had been induced with hypertonic saline, for investigation of respiratory 
disease. In 1964 Cleland described DTT as capable of splitting mucoprotein disulphide 
bonds [28]. In 1978 Wooten and Dulfano used it to break up mucus and disperse cells 
[208]. In 1992 Pin et al. [151] investigated asthma using induced sputum samples. A 
Medline search of complete papers containing the key words “induced sputum” identifi ed 
more than 650 published since 1992.
2.4.1. Reproducibility
Sputum is a useful source of cells and soluble markers that can be used in investigating 
cellular and biochemical characteristics of airway infl ammation. Since methods used to 
induce production of sputum and process differ, each needs to be validated separately. 
However, few reports of validation studies have been published so far [99, 153, 184, 
194].
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Indices related to cells in sputum have been shown to be reproducible and responsive to 
treatment [151, 156, 158, 180, 194, 202]. It has been shown that numbers of eosino-
phils in induced sputum from asthmatic patients decrease signifi cantly following treat-
ment with inhaled steroids [150]. Gibson et al. [51] studied sputum plugs from asth-
matic patients who had produced sputum spontaneously. They showed that differential 
cell counts in sputum samples from a given patient on two consecutive days were highly 
reproducible. In a study by in’t Veen et al. [194], sputum samples were induced with 
hypertonic saline in patients with asthma on two consecutive days. Entire samples, inclu-
ding both sputum plugs and saliva, were examined. No signifi cant differences in fi ndings 
relating to neutrophils, eosinophils, lymphocytes, albumin, fi brinogen, IL-8 or ECP were 
found between samples obtained on successive days [194]. Recent reports have shown that 
although numbers of eosinophils and lymphocytes did not differ signifi cantly between 
sputum samples collected 24 hours apart, there were signifi cantly more neutrophils in the 
second sample [76].
2.4.2. Comparison of fi ndings obtained using induced sputum samples, 
         bronchoalveolar lavage fl uid and biopsy specimens
Indices of airway infl ammation in induced sputum have been compared with those 
obtained using other methods. Fahy et al. studied markers of infl ammation and cells in 
samples obtained by sputum induction, bronchial washing and BAL from healthy and ast-
hmatic subjects [40]. Their principal fi ndings were that concentrations of cells and chemi-
cals were higher in induced sputum samples than in bronchial washings or BAL material. 
Induced sputum samples also contained higher percentages of neutrophils and eosinophils, 
and higher concentrations of ECP, albumin and mucin-like glycoprotein, probably because 
they were less dilute. The constituents of induced sputum samples more closely resemb-
led those of bronchial washings than those of BAL material. Bronchial biopsy specimens 
contained greater numbers of lymphocytes [120]. In some studies a signifi cant correlation 
has been found between numbers of eosinophils in BAL material or bronchial biopsy spe-
cimens and numbers of eosinophils in induced sputum samples, in others no correlation 
has been found [64, 120].
2.4.3. Infl ammatory mediators
There has recently been an increasing tendency to determine numerous infl ammatory 
mediators, refl ecting different aspects of airway infl ammation, in sputum processed using a 
variety of methods (Table 3). Levels of most mediators have been determined for research 
purposes. The utility of such determinations as a clinical tool has not been fully investiga-
ted. Methods of sputum induction have, however, conveyed important benefi ts in relation to 
diagnosis in patients with airway infl ammation, and comparisons of treatment strategies.
Sputum induction and mediator determination have been used in various clinical situ-
ations. Induced sputum samples have been examined to monitor airway infl ammation 
and effect of treatment in asthma and COPD [27, 87, 156, 158, 171]. By choosing an 
appropriate mediator or ratio, various patient groups have been distinguished one another, 
and from healthy subjects [48, 95]. Concentrations of ECP, tryptase, fi brinogen and albu-
min have been found to be higher in sputum from subjects with asthma than from normal 
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subjects [38]. ECP and tryptase concentrations have correlated with sputum eosinophils 
and metachromatic cells (i.e. mast cells and basophils) in differential cell counts.
Table 3. Mediators studied in sputum
Description                                    Mediator* References 
Cytokines                                         IL-5, IL-6, IL-8, IL-10, IL-12, TNF-α,  1, 85, 96, 99, 103, 163, 
                                                   TGF-β, eotaxin, RANTES 173, 186, 213, 216
Eosinophil granule proteins              ECP, EPO, EPX, MBP 72, 95, 163
Neutrophil products                        MPO, HNL 72, 95
Markers of microvascular leakage     Albumin, fi brinogen, β
2
-macroglobulin 174
Eicosanoids                                      Leukotrienes, prostaglandins 143
Proteases                                          Elastase, tryptase, cathepsin B,  18, 115, 200
                                                   matrix metalloproteinase-9
Protease inhibitors                           α-1-antitrypsin 74
Soluble products                              Nitric oxide 84, 90, 163
Others                                             Substance P, endothelin-1, VCAM-1,  22, 45, 131, 132, 
       immunoglobulins 133, 173
*IL, interleukin; TNF-α, tumour necrosis factor α; TGF-β, transforming growth factor β; VCAM-1, 
vascular cell adhesion molecule 1.
Analysis of induced sputum samples has also allowed study of timing of cellular events 
after allergen challenge. Pin et al. [152] demonstrated an increase in sputum eosinophil 
levels 24 hours after allergen inhalation in subjects who developed late asthmatic respon-
ses and metacholine airway hyper-responsiveness. Fahy et al. [39] showed that levels of 
ECP and histamine in induced sputum supernatants were higher four hours after allergen 
challenge than at baseline, and remained so for 24 hours after challenge. 
It has been suggested that sputum samples can only be examined in research centres. 
However, initial attempts have been made to introduce sputum induction and sputum 
processing methods at general-practitioner level, with good results. In primary-health-care 
centres, adequate induced sputum samples have been obtained in 91% of patients with 
prolonged cough. Infl ammatory cells were examined in smears and levels of markers of 
infl ammation were determined [172]. The results showed that concentrations of ECP and 
EPO were more often high in patients with prolonged cough than in healthy individuals 
[172]. A simplifi ed method of sputum examination has been used in an epidemiological 
study involving 1000 subjects (Petäys T, unpublished).
2.4.4. Immunocytochemical analysis
To date, few immunocytochemical studies have been conducted in relation to sputum [53, 
77, 113, 161]. In a study by Popov et al. [161], portions of fresh sputum were selected and 
exposed to different volumes of DTT for different times. The resulting cell suspensions 
were used for preparing cytospins for immunocytochemical staining for GM-CSF, EG2 
(monoclonal antibody against ECP), TNF-α and IL-8. Exposure to high concentrations of 
DTT for lengthy periods tended to increase total cell counts and signifi cantly decreased 
EG2 staining but had no effect on differential cell counts or cytokine components. In a 
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study by Lensmar et al. [113], complete expectorated sputum was used to characterize 
macrophages by means of seven monoclonal antibodies, using an indirect immunocytoche-
mical method. The effect of DTT was investigated using BAL samples. No difference in 
expression of any of the seven antibodies was found. The results of the study indicate that 
induced sputum could be used in immunocytochemical studies of cell-surface markers.
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3.AIMS OF THE STUDY
The specifi c aims of the study were as follows:
1)       To establish a protocol for sputum induction and to validate sample processing.
2)       To examine the effects of different fi xation and permeabilization methods in rela-
tion to immunocytochemical studies.
3)       To study the cell specifi city of granulocyte markers, using immunocytochemical 
staining.
4)       To study early asthma using sputum samples, and to determine the effects of treat-
ment on infl ammation markers.
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4. SUBJECTS, MATERIALS AND METHODS
4.1. Study population and design
The population in studies I to V consisted of 171 patients and 97 healthy controls. 
Twenty-nine of the subjects were children (14 patients and 15 healthy controls). The cha-
racteristics of the study populations are shown in Table 4.
The Ethics Committee of the Skin and Allergy Hospital (Helsinki University Central 
Hospital, Finland) had approved the studies, and all subjects or their parents gave infor-
med consent to participation.
4.1.1. Study I
This was an open cross-sectional study. The methodological aim was to compare cellular 
profi les and infl ammatory markers by two sputum-processing methods in four study 
groups and to validate the sputum method processing.
Four groups were studied: 42 healthy subjects, 10 patients with acute respiratory infec-
tion, eight patients with COPD, and 17 patients with asthma. The healthy subjects, with 
no history of asthma, other respiratory symptoms or respiratory infection within the pre-
vious four weeks, were recruited from hospital staff and their relatives. PEF values lay 
within the normal range [201]. Ten otherwise healthy subjects who had had an acute res-
piratory tract infection for less than a week were also included. The microbial origin of 
the infection was not studied. Symptoms were those characteristic of acute viral infection 
of the respiratory tract. The patients had normal PEF values. Eight patients previously 
diagnosed as suffering from COPD [4] and smoking histories of 20 to 80 pack-years were 
included. They were clinically stable. Mean FEV
1
 was 43% of that predicted, with less 
than a 10% bronchodilatation response to inhaled salbutamol (Buventol Easyhaler®, Orion 
Pharma, Espoo, Finland). All asthma patients had reversible airway obstruction with either 
at least a 15% bronchodilatation response in FEV
1
 to 200 µg of inhaled salbutamol, or 
at least a 20% diurnal variation in PEF values for at least three days during a two-week 
follow-up period. All asthmatics showed increased bronchial responsiveness to inhaled his-
tamine, with a mean PD
20 
FEV
1
 of 0.35 mg [182]. No COPD or asthma patient had recei-
ved anti-infl ammatory medication (inhaled corticosteroid, sodium cromoglycate or sodium 
nedocromil), or had had an exacerbation or respiratory infection within the previous four 
weeks.
In three patient groups and the healthy control subjects cellular profi les and infl amma-
tory markers obtained using two sputum-processing methods were compared in an open 
cross-sectional study. The sputum-processing method used in the study was also valida-
ted. Patients with asthma and COPD met American Thoracic Society criteria [4]. Skin-
prick tests were performed and single PEF measurements made in all subjects. Dynamic 
spirometry was undertaken in patients with asthma and COPD. Bronchial responsiveness 
to histamine was measured in the asthma patients.
Sputum production was induced in all subjects by inhalation of 5 ml of a 3% NaCl solu-
tion, using a small ultrasonic nebulizer. Sputum plugs were collected and divided into 
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two, to allow comparison of two methods of sputum processing (see 4.4. Sputum proces-
sing). To allow determination of within-subject variability in relation to induced sputum, 
16 subjects provided induced sputum samples twice, one week apart. The samples were 
analysed using both methods.
4.1.2. Study II
The aim of this methodological study were fi rstly to immunolabel sputum and BAL-fl uid 
cells with antibodies directed to intracellular markers and to study their cell-specifi city, 
and secondly to fi nd a reliable fi xation method to prepare samples and to detect intracel-
lular antigens. 
Induced sputum samples were obtained from 14 subjects, four healthy individuals, two 
patients with acute respiratory infection, six with asthma, one with COPD and one with 
prolonged cough. Most of the patients were the same as in Study I. BAL samples were 
obtained from fi ve patients, two with asthma, one with COPD and two with prolonged 
cough of unknown cause. Both sputum and BAL samples were obtained from one patient 
with asthma.
The aims of this methodological study were, fi rstly, to immunolabel cells of sputum and 
BAL fl uid using antibodies against intracellular markers and to study their cell-specifi city, 
and, secondly, to develop a reliable fi xation method for preparing samples and detecting 
intracellular antigens. Sputum production was induced, plugs were collected and sputum 
was processed (see 4.4. Sputum processing). Bronchoscopy and BAL were carried out in 
accordance with standard protocols [209]. Cytospins for sputum and BAL cells were pre-
pared (see 4.7.2. Cytospin preparations) and subjected to various procedures (see 4.7.3. 
Permeabilization and fi xation).
4.1.3. Study III
Twenty-three patients with early or suspected asthma were recruited into an open cross-
sectional study. The aim was to identify the laboratory test most useful in the diagnosis 
of early or suspected asthma. The patients had had one or more of the following asthma 
symptoms for less than a year: cough, sputum secretion, chest tightness with wheezing. 
They all had had need for asthma medication. Patients with chronic bronchitis, respiratory 
infection or prolonged coughing of undefi ned origin were excluded. 
Two reference populations were also included in the study. Nineteen patients had had 
asthma for between two and 52 years (mean 13 years). All except one had received anti-
infl ammatory medication. At the time of the study 11 patients suffered from exacerbation 
of symptoms and needed more effi cacious medication. In eight patients the asthma was 
in a stable phase. A healthy control group consisted of 10 volunteers. None were atopic, 
none-smoked, none had exhibited previous symptoms of asthma, and none had current 
symptoms of asthma.
Patients with early or suspected asthma visited the hospital three times, twice before 
diagnosis, once after PEF follow-up. During the fi rst two visits, consent to participate in 
the study was obtained. Lung-function and skin-prick tests were performed. Instructions 
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regarding PEF follow-up were given. During a subsequent visit, induced sputum, blood 
and urine samples were obtained.
The patients with chronic asthma selected had been referred to the Outpatient Clinic of 
the Hospital. During their referral visit, induced sputum, blood and urine samples were 
obtained. Lung function had been measured and PEF follow-up and skin-prick tests per-
formed earlier. The healthy subjects paid one visit, during which induced sputum, blood 
and urine samples were obtained and skin-prick tests were conducted. Lung function was 
not measured.
4.1.4. Study IV
In this open longitudinal study eighty patients with newly detected asthma were recrui-
ted. The aim was to evaluate the usefulness of infl ammatory markers in induced sputum, 
serum and urine as markers of asthmatic infl ammation in adults. To study the effects of 
different treatments, marker levels were also examined after medication.
Patients had exhibited symptoms (cough, sputum secretion, wheezing, dyspnoe or chest 
tightness) for less than one year and had at least one of three abnormal lung-function test 
results:
1)       PD
15 
≤ 1.6 mg on histamine challenge, 
2)       FEV
1
 improvement of > 15% after inhalation of a β
2
-agonist (0.4 mg rimiterol 
(Pulmadil, 3M)), 
3)       a PEF diurnal variation of > 15% and a PEF increase of > 15% after inhalation of 
a β
2
-agonist at least once during a two-week follow-up period.
Exclusion criteria were treatment with anti-infl ammatory medication (corticosteroids, 
chromones, theophylline), lung disease other than asthma, and a respiratory tract infection 
in the previous four weeks. On the basis of symptom history, lung-function parameters 
and symptom scores, 61 patients (76%) were classifi ed as having mild asthma and 19 
patients (24%) as having moderate asthma.
Thirty healthy, non-atopic, non-smoking control subjects were recruited from hospital 
staff. Exclusion criteria were past or present symptoms of asthma or other chronic respira-
tory disease, a respiratory tract infection in the preceding four weeks, and hyper-responsi-
veness to histamine.
Patients were allotted at random to one or other of two treatment groups. At baseline, 
they were similar in relation to all clinical parameters examined. Forty-one budesonide-
group patients (BUD) received 1.2 mg inhaled budesonide (Pulmicort Turbuhaler, Astra-
Draco AB, Lund, Sweden) per day, in two doses. The patients could also inhale the bron-
chodilator terbutaline (0.5 mg Bricanyl Turbuhaler, Astra-Draco AB, Lund, Sweden) when 
needed. Thirty-nine terbutaline-group patients (TER) took only terbutaline when needed. 
The fi rst treatment period in both groups lasted for six weeks. The patients in the TER 
group then switched to budesonide, with which they were treated for two weeks as desc-
ribed for the BUD group. No phase of the study was blind for the patients. 
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All patients measured morning PEF for two weeks. The best of three measurements was 
recorded. The two-week measurement period was repeated two or three times, for all 
patients before inclusion and during treatment weeks fi ve and six, and, in the case of 
terbutaline-treated patients, during treatment weeks seven and eight. At the times of PEF 
measurement, patients also evaluated the subjective symptoms of their asthma.
Patients visited the hospital three times, twice before treatment and after six weeks of tre-
atment. The TER group paid an additional visit after two weeks of budesonide treatment. 
During the fi rst two visits, consent to participation in the study was obtained, and lung-
function and skin-prick tests were performed. During subsequent visits, sputum, blood, 
and urine samples were obtained. Controls contributed samples once.
4.1.5. Study V
In this open longitudinal study the usability of sputum induction was examined in 
children. To study the effects of different treatments, marker levels were also examined 
after medication.
Fourteen consecutive prepubertal children with newly detected asthma were examined in 
an open longitudinal study. Diagnosis was based on a positive history, combined with 
meeting of at least one of the following criteria: diurnal variation of ≥ 20% in PEF or a ≥ 
15% increase in FEV
1
 during a bronchodilating test or a ≥ 15% decrease in FEV
1
 during 
an exercise test. The patients had not had any anti-infl ammatory treatment for asthma 
before the study, were suffering from no other atopic diseases, and were taking no other 
medication for an atopic condition. Fifteen healthy children served as a control group. 
They had normal lung function parameters and no history of atopy or any evidence of 
allergen-specifi c IgE (negative result in Phadiatop Combi test, Pharmacia Diagnostics, 
Uppsala, Sweden).
After a diagnosis of asthma was confi rmed, each patient entered the study and treatment 
was started. The patients inhaled budesonide (Turbuhaler, Astra-Draco AB, Lund, 
Sweden), 800 µg/m2/day divided into two doses for the fi rst month and 400 µg/m2/day as 
two doses for the next fi ve months. During the following six months, they inhaled nedo-
cromil (Tilade, Fisons Ltd., UK), 4 mg three times a day, via a Nebuhaler (Astra-Draco 
AB, Lund, Sweden). They were permitted to use β
2
-agonists (Bricanyl, Astra-Draco AB, 
Lund, Sweden, 0.25 mg/dose) as needed. Two children had an exacerbation of asthma soon 
after the switch to nedocromil, and were therefore restarted on budesonide. They were 
excluded from analysis at 12 months.
Subjective symptoms were evaluated, pulmonary function (spirometry, histamine-chal-
lenge test) was assessed, and blood, morning urine and sputum samples were taken before 
treatment, at one month and at six and 12 months. The interval between diagnosis of 
asthma and obtaining the fi rst sputum sample before treatment was one to three days. In 
healthy controls, pulmonary function was assessed by spirometry, and samples were taken 
similarly.
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4.2. Clinical methods
4.2.1. Lung-function tests (Studies I to V)
Flow-volume spirometry. The resting spirometry was carried out according to the Ameri-
can Thoracic Society (ATS) with a fl ow-volume spirometer (Vitalograph, Vitalograph Ltd., 
Buckingham, UK). Values are expressed as percentages of predicted (reference) values for 
adults [201] and children [159].
Histamine-challenge test. Bronchial responsiveness was tested by means of the histamine-
challenge test. Non-cumulative histamine doses of 0.025, 0.1, 0.4 and 1.6 mg were inha-
led, and FEV
1
 values were measured 90 seconds after each inhalation. Results were con-
sidered positive if the dose provoking a 15% reduction in FEV
1
 (PD
15
) was less than or 
equal to 1.6 mg of histamine [182].
Peak expiratory fl ow. Subjects measured their PEF values over two-week periods, twice a 
day, before and after two puffs of inhaled bronchodilator (0.5 mg of terbutaline per puff). 
Reversible bronchial obstruction was considered to be present if PEF values increased by 
at least 15% after the b
2
-agonist at least once during a two-week follow-up period and/or 
PEF diurnal variation was over 15% from day to day. PEF values were expressed as per-
centages of the predicted value for the patient. Reference values were those of Gregg and 
Nunn [61].
4.2.2. Skin-prick tests (Studies I to V)
Skin-prick tests were performed using 11 common environmental allergens (Soluprick 
SQ, 10 HEP, ALK-Abello, Hørsholm, Denmark). The air-borne allergens used were birch, 
timothy, meadow fescue and mugwort pollen, horse, dog, cat and cow dander, the mite 
Dermatophagoides pteronyssinus and spores of the mould Cladosporium herbarum. A 
patient was defi ned as atopic if one or more allergens gave a weal equal to or larger than 
3 mm, and positive (histamine dihydrochloride, 10 mg/mL) and negative (solvent) control 
solutions gave the expected results [6].
4.2.3. Asthma symptom score (Studies IV and V)
Study IV. At the time of morning PEF measurements patients evaluated subjective symp-
toms they had experienced during the previous 24 hours, using a score from 0 (no symp-
toms) to 10 (most severe discomfort). Symptom scores are reported as means for two-week 
periods.
Study V. Symptoms of asthma were evaluated using a visual analogue scale (from 0 (none) 
to 10 (severe)) which patients were asked to mark at during each visit, describing symp-
toms since the last visit.
4.2.4.  Blood and urine samples (Studies III to V)
Numbers of eosinophils were counted in EDTA-preserved blood using an automated cell 
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counter (Technicon H2, Technicon, U.S.A). Blood eosinophils were expressed as cells x 
109/L; a value of 0.43 cells x 109/L being the normal upper limit (reference values deter-
mined in own laboratory in the Skin and Allergy Hospital, unpublished).
To obtain serum for determination of levels of infl ammatory markers, blood was collected 
by venipuncture, using SST gel tubes (Becton-Dickinson, UK) and allowed to clot at room 
temperature for one hour (±10 minutes). Serum was separated by centrifugation at 1350 
g for 10 minutes and stored at -20°C until analysed.
First urine in the morning was sampled and freeze-dried without preservatives until 
marker analysis. To adjust for the variable amounts of water excreted in the urine, urinary 
EPX results are reported as EPX/creatinine (µg/mmol) ratios. Urinary creatinine was 
determined using Jaffe´s method [189].
4.3. Sputum induction (Studies I to V)
Studies I and II. Sputum was induced by inhalation of 5 ml of 3% NaCl solution, using 
a small ultrasonic nebulizer (Omron U1, Omron, Germany). The output is about 0.25 
ml/min and the mean aerodynamic mass median diameters of the nebulized saline solution 
range from 1 to 7 µm, according to the manufacturer.
Studies III to V. Sputum was induced by inhalation of hypertonic saline generated by an 
ultrasonic nebulizer (Spira Ultra, Spira Ltd, Hengityshoitokeskus, Hämeenlinna, Finland). 
The nebulizer was on maximum settings and was fi lled with 4 ml of 5% NaCl. According 
to the manufacturer, the nebulizer generates particles of diameters ranging from approxi-
mately 1.1 µm to 2.2 µm, and has an output of 0.6 ml/min.
Before coughing up sputum, subjects were asked to rinse their mouths, swallow saliva 
and water, and blow their noses, to minimize contamination with saliva and post-nasal 
drip. Subjects were asked to cough during and after inhalation, and to expectorate into 
empty containers. Induction was discontinued once an adequate sputum sample had been 
obtained or 15 minutes had passed. No premedication was used. To check lung function, 
PEF measurements were made before and after sputum induction. If PEF decreased by 
more than 10%, the subject was treated with two puffs of 0.5 mg of terbutaline. None of 
the subjects experienced marked adverse effects.
4.4. Sputum processing (Studies I to V)
In all of the studies, sputum was processed within two hours. It was stored in a refrigera-
tor at +4°C pending processing.
Study I. Sputum samples were transferred to a Petri dish and the more viscous parts col-
lected using forceps. Sputum plugs (all sputum macroscopically free of salivary contami-
nation) were fi rst mixed with forceps and then divided into two parts, to allow two met-
hods of sputum processing to be compared. The portions of the samples were processed 
either (1) by a reference method (for released markers) described by Pizzichini et al. [153] 
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to collect cells for cytospins and cell-free supernatant, or (2) by the method being investi-
gated (for total markers), in which cells were lysed, and marker proteins inside and outside 
the cells solubilized.
1) In the reference method, a four-fold volume of 6.5 mmol/L dithiothreitol (DTT) (Spu-
tolysin®, CalbioChem, LaJolla, California, USA; diluted 10-fold in distilled water) was 
added to the sputum sample and the mixture was incubated for 15 minutes on a roller 
mixer at room temperature. An equal volume of phosphate-buffered saline (PBS) was 
added, and incubation continued for another fi ve minutes. The mixture was fi ltered 
through a 53-µm mesh nylon fi lter (Nybolt PA-53/35, Seidengaze, Germany). Sputum 
cells were separated by centrifugation at 800 g for 10 minutes and the supernatant was 
collected for measurements of fl uid-phase markers.
Cells obtained after centrifugation were resuspended in 1 ml of PBS and the total number 
of cells was determined using a haemocytometer. Viability was measured by means of 
the Trypan Blue exclusion test (Trypan Blue Stain 0.4%, GibcoBRL, Life Technologies, 
UK). The cell suspension was cytocentrifuged (Cytospin 3, Shandon, Astmoor, UK) on to 
Vectabond-treated (Vectabond® Reagent, Vector Laboratories, Inc., CA, USA) microscope 
slides at 450 rpm for four minutes. Slides were air-dried for at least 30 minutes. One slide 
was used for differential staining using the May-Grünwald-Giemsa (MGG) method. Two 
slides were fi xed using Carnoy’s fi xative and stained using toluidine blue for detection 
of metachromatic cells. A minimum of 400 non-squamous cells was counted on MGG-
stained slides, 1500 on toluidine-blue-stained slides, using a standard light microscope. 
Results were expressed as a percentage of the total non-squamous cell count.
2) In the method being investigated, a four-fold volume of 6.5 mmol/L DTT was added to 
the sputum sample, as in the case of the reference method, and the mixture was incubated 
for 15 minutes on a roller mixer at room temperature. In contrast to the reference method, 
a fi ve-fold volume of CTAB (N-cetyl-NNN-trimethylammonium bromide) reagent was 
added after 15 minutes and the mixture was incubated for one hour on a roller mixer. 
The CTAB reagent contained 0.5% of CTAB, 0.4% of human serum albumin (HSA), and 
100 mmol/L phosphate-buffered saline (PBS), pH 7.2. This procedure led to cell lysis, 
and release and solubilization of granulocyte markers, inside and outside the cells [19]. 
Sputum supernatant was separated from cell debris by centrifugation at 800 g for 10 
minutes. The resulting clear suspension was aspirated, divided into portions and stored in 
Eppendorf tubes at -20°C for subsequent marker assay.
Study II. Sputum was processed by means of the method described by Pizzichini et al. 
[153] (Study I, method 1) to collect sputum cells for immunocytochemical experiments.
Study III. Native sputum samples were used to prepare microscope slides. The slides were 
air-dried and stained with eosin-methylene blue. To liquefy the sputum, its volume was 
determined and the complete sample, including saliva, was diluted with an equal volume 
of a 10% solution in water of Sputolysin® (CalbioChem, LaJolla, California, USA). This 
solution contained 6.5 mmol/L DTT. The mixture was incubated for 15 minutes at room 
temperature. The sample was centrifuged for 10 minutes at 800 g. The pellet material 
was used for cytology and the supernatant for marker assay.
37
Studies IV and V. The bronchial origin of the sputum was confi rmed cytologically by 
spreading part of a native sputum sample thinly on two microscope slides and staining by 
means of the Papanicolaou method after ethanol fi xation. The volume of the rest of the 
sample was determined and an equal volume of 6.5 mmol/L DTT solution (Sputolysin®, 
CalbioChem, LaJolla, California, USA; diluted 10-fold) added. The mixture was vortexed, 
incubated for 15 minutes at room temperature, and stored at -20  C till analysed. The 
thawed sample was incubated for one hour with an equal volume of PBS, pH 7.2, contai-
ning 0.4% CTAB (to disrupt cells and solubilize proteins) and 0.25% HSA. The sample 
was then centrifuged at 600 g for 10 minutes to remove cell debris.
4.5. Biochemical analysis (Studies I, III to V)
Concentrations of ECP (µg/L) in thawed sputum and serum were determined using an 
immunoassay kit (CAP System FEIA ECP, Pharmacia & Upjohn Diagnostics, Uppsala, 
Sweden), levels of MPO (µg/L) using a double-antibody radioimmunoassay kit (MPO 
RIA, Pharmacia & Upjohn Diagnostics, Uppsala, Sweden). Concentrations of EPX (µg/L) 
in urine, sputum and serum were determined using a double-antibody radioimmunoassay 
research kit (EPX RIA, Pharmacia and Upjohn Diagnostics, Uppsala, Sweden). Commer-
cial kits were used according to manufacturers’ instructions. Concentrations of EPO (µg/L) 
and HNL (µg/L) were determined using prototype kits (CAP System FEIA, Pharmacia & 
Upjohn Diagnostics, Uppsala, Sweden). If necessary, samples were diluted with the corres-
ponding assay diluent. The fi nal results were adjusted for dilution arising from processing 
and any other dilution necessary (high levels, over measuring range). All measurements 
were performed in duplicate.
The principle of the assays for ECP, EPO and HNL is as follows. Anti-ECP (EPO, HNL) 
antibody coupled to a solid phase (Sepharose in ImmunoCAP) reacts with ECP (EPO, 
HNL) in the sample. After washing, β-galactosidase-anti-ECP (EPO, HNL) reacts with 
bound ECP. After another wash, bound ECP enzyme-anti-ECP reacts with the substrate 
4-methylumbelliferyl-β-D-galactoside, forming a fl uorescent product, levels of which can 
be measured using a fl uorometer.
ECP standards were calibrated against pure ECP prepared according to Peterson et al. 
[146]. EPX standards were calibrated against pure EPX prepared according to Peterson 
and Venge [147]. EPO used in a standard had been purifi ed according to Carlsson et al. 
[21]. MPO standards were calibrated against an international reference standard [2, 140]. 
HNL used in a standard had been purifi ed according to Xu et al. [210]. All standards were 
included in the reagent kits and were commercial. The specifi cations for infl ammatory 
marker assays are summarized in Table 5.
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Table 5. Performance characteristics for serum application as reported by the manufacturer 
(Pharmacia&Upjohn, Sweden)
Assay                Measuring Detection Recovery Coeffi cient of variation (%) 
                         Range (µg/L) limit (µg/L)  (%)  Intra-assay  Interassay
ECP                  2 - 200  < 0.5 81 - 91 1.8 - 3.1 3.8 - 5.0
EPX                  3 – 400 < 3 91 - 105 4.4 - 5.3 4.8 - 10.6
EPO                  0.5 – 200 < 0.5 N.a < 9 < 9
MPO                 8 – 1000 < 8 104 - 125 4.9 - 8.3 5.8 - 12.3
HNL                 20 – 600 < 20 N.a. < 8 < 8
N.a. = not available
In Study V, sputum ECP levels were adjusted for dilution (saliva, saline, etc.), and con-
centrations for sputum albumin and urea were determined. Levels of sputum albumin were 
determined using an unpublished in-house immunoturbidometric method [189]. Sputum 
urea concentrations were determined using a urease/glutamate-dehydrogenase method and 
a Hitachi analyser [189]. Results were expressed as ratios of sputum ECP/albumin (µg/mg) 
and sputum ECP/urea (µg/mmol).
4.6. Staining methods (Studies I to V)
Several staining methods were used. All analyses were blind with respect to clinical characte-
ristics of subjects. If examination of slides revealed macrophages or ciliated epithelial cells, the 
sample was considered to be of bronchial origin and was included in the study.
Eosin-methylene blue (Study III). Native sputum was spread thinly on two microscope slides. 
The slides were air-dried for at least 30 minutes and stained with eosin and methylene blue 
(Merck, Darmstadt, Germany) [123]. They were examined under a light microscope to deter-
mine numbers of eosinophils and neutrophils in a semiquatitative manner, as smears cannot be 
used for differential cell counting. Proportions of eosinophils, neutrophils and macrophages to 
total numbers of cells were determined on a scale from one minus (-) to four pluses (++++) 
(expressed as 0, 0.5, 1, 2, 3 or 4) (Table 6), on the basis of Hansel’s model scale [69]. To standar-
dize interpretation, the analyst used a set of drawings showing typical microscope fi elds [69].
Table 6. Proportions of eosinophils and neutrophils in sputum determined by means of a semi-
quantitative method. Proportions of macrophages were assessed using the scale: no macrophages on 
slide, poor specimen (-); macrophages on slide, good specimen (+). Instructions for interpretation are 
intended mainly as a guide and are laboratory-specifi c. The scale is used in laboratory of the Skin 
and Allergy Hospital, Helsinki University Central Hospital [65].
Score Eosinophilic cells on entire slide Neutrophilic cells on entire slide 
(-) = 0 0 or very few cells 0 or few cells 
(+/-) = 0.5 1 - 3 cells in visual fi eld, 5 - 10 cells/streak  Scanty (hard to see)
(+) = 1 3 - 5 cells in visual fi eld, streak of   Moderate numbers (easily seen)
 5 - 10 cells or one fi nding of about
 20 - 30 cells (signifi cant)
(++) = 2 Several streaks of about 20 - 30 cells Several streaks fairly rich in cells
(+++) = 3 Streaks rich in cells Abundant over entire slide
(++++) = 4 Extremely abundant fi ndings Extremely abundant fi ndings
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Papanicolaou (Studies III to V). Slides were made either immediately, using a fresh 
sample, by spreading sputum thinly on two microscope slides (Studies IV and V), or from 
cell-pellet material (Study III). Cells were fi rst fi xed, then stored in ethanol before stai-
ning. Slides were stained using the Papanicolaou procedure [141] and examined under a 
microscope to determine numbers of eosinophils and neutrophils, semiquantitatively. The 
scale was the same as that described previously.
May-Grünwald-Giemsa (MGG) (Studies I and II). Cytospins from sputum and BAL-
fl uid suspensions were allowed to dry in the air for 30 minutes and were then stained 
using the MGG method [124]. Reagents were from Oy Reagena Ltd, Finland. At least 
400 non-squamous cells, including eosinophils, neutrophils, lymphocytes, macrophages 
and ciliated epithelial cells, were counted differentially. Results were expressed as percen-
tages of total non-squamous counts.
Toluidine blue (Study I). Sputum and BAL-fl uid cytospins were fi xed using Carnoy’s 
fi xative (60% ethyl alcohol, 30% chloroform, 10% glacial acetic acid) and stained using 
toluidine blue (Merck, Darmstadt, Germany) for detection of metachromatic cells (baso-
phils, mast cells) [206]. A minimum of 1500 non-squamous cells was counted using a 
standard microscope. The results were expressed as percentages of total non-squamous cell 
counts.
Mayer’s haematoxylin (Study II). After immunolabelling, sputum and BAL-fl uid cell 
samples were counterstained with Mayer’s haematoxylin [125] (Merck, Darmstadt, Ger-
many) for six minutes and rinsed in tap water. Cells were counterstained to a single series 
to minimize batch-to-batch variation.
4.7. Immunocytochemical methods (Study II, unpublished)
4.7.1. Bronchoalveolar lavage and sputum samples (Study II)
Bronchoalveolar lavage. Subjects were premedicated with diazepam (10 mg orally) and 
atropine (0.1 mg/10 kg intramuscularly). After local anaesthesia with a 2% lidocaine solu-
tion, a fl exible fi bre-optic bronchoscope (Olympus BF, type IT 30; Olympus Co., Tokyo, 
Japan) was passed through the mouth into the trachea. Two hundred millilitres of sterile 
normal saline at 37°C were used to wash out the right lower lobe. BAL samples were 
aspirated using gentle suction, collected in a syringe, and processed immediately. The fi rst 
two washes recovered were used for diagnostic purposes, the third for Studies V and VI. 
Washes were transported immediately to the laboratory and processed. Cells were separa-
ted from BAL fl uid by centrifugation at 800 g for 10 minutes at room temperature. Cells 
pelleted by centrifugation were resuspended in PBS to 1 x 106 cells/ml, and cell viability 
was measured using the Trypan Blue exclusion test (Trypan Blue Stain 0.4%, GibcoBRL, 
Life Technologies, UK).
Sputum. Sputum was induced by inhalation of hypertonic saline (see 4.3. Sputum induc-
tion). Sputum samples were treated using a method described by Pizzichini et al. [153] to 
obtain sputum cell suspensions.
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4.7.2. Cytospin preparations (Study II)
Suspensions of sputum and BAL cells were centrifuged (Cytospin 3, Shandon, Astmoor, 
UK) on to Vectabond-treated (Vectabond Reagent, Vector Laboratories Inc., CA, USA) 
microscope slides at 450 rpm for six minutes. Slides were air-dried for at least 30 minutes. 
One slide was stained using the MGG method and counted differentially. Cytospin slides 
for immunocytochemistry were processed immediately, or wrapped and stored at -20°C 
(at least two weeks) prior to fi xation and permeabilization. The effects of freezing and tha-
wing on immunocytochemical results were examined in relation to four sputum and BAL 
cytospin slides by studying identical slides that had and had not been frozen prior to fi xa-
tion and permeabilization.
4.7.3. Permeabilization and fi xation (Study II, unpublished)
Frozen cytospin samples were slowly thawed out, then subjected to various procedures. In 
Study II, sputum and BAL cells were treated only using a method (treatment with Ortho 
Permeafi x) which had been found to be optimal. Otherwice slides were treated with all 
methods. Procedures were as follows:
1)       Air-drying of slides (no fi xation); 
2)       Treatment with acetone for 15 minutes at room temperature;
3)       Treatment with methanol for 10 minutes at room temperature;
4)       Treatment with methanol overnight at -20°C;
5)       Treatment with periodate-lysine-paraformaldehyde (PLP) (containing 0.01 M peri-
odate, 0.075 M lysine and 2% paraformaldehyde (PFA)) [126] for 30 minutes;
6)       Treatment with 10% formaldehyde (FA) for 10 minutes;
7)       Treatment with IntraPrep (IntraPrep™ Permeabilization Reagent, Immunotech, 
France) for 30 minutes. The washing solution included a saponin in all steps.
8)       Treatment with Ortho Permeafi x (OPF) (Ortho Diagnostic Systems Inc., UK) for 
40 minutes. OPF was used undiluted, as a concentrate.
4.7.4. Immunocytochemical labelling (Study II)
After fi xation and/or permeabilization, all slides were incubated for 15 minutes in PBS 
with 0.2% bovine serum albumin (BSA) prior to addition of a primary antibody (Table 
7). Incubation with a primary antibody was performed at room temperature in a humid 
chamber for 30 minutes. It was terminated by washing with PBS containing 0.2% BSA. 
The antigen-antibody complex was visualised using a commercial alkaline phosphatase-
anti-alkaline phosphatase (APAAP) kit (K670, Dako, Glostrup, Denmark) and a Fast 
Red substrate, in accordance with manufacturer’s instructions. In negative controls, the 
primary antibody was omitted. Samples were counterstained with Mayer’s haematoxylin 
for six minutes. Cover glasses were mounted using Dako Fluorescent Mounting Medium 
(Dakopatts, Glostrup, Denmark). Cells were immunolabelled and counterstained to a 
single series to minimize batch-to-batch variation.
Identifi cation of cell types was based on cell morphology with reference to corresponding 
MGG-stained slides. At least 400 non-squamous cells were counted differentially (see 
4.6. Staining methods). Immunostained cell samples were examined microscopically (Leica 
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DRMB, Germany). Two people (TM, LS) independently counted the cells that had stained 
red, showing were antigens were located, in 10 high-power fi elds at 400-fold magnifi ca-
tion. Results were expressed as percentages of positive cells. Fuji 200 negative fi lm was 
used for photography.
Table 7. Characteristics of antigens and antibodies used
Antigen                 Size             Location                           Antibody* Concentration 
Eosinophil              67 kDa        Eosinophil granules,          Mouse anti-human   2 µg/ml
peroxidase, EPO                          matrix                               eosinophil peroxidase,
                                                                                             one clone (IgG
1
)
Eosinophil cationic 18-20 kDa   Eosinophil granules,          Mouse anti-human   1 µg/ml
protein, ECP                               matrix                               eosinophil cationic protein,
                                                                                             clone EG2 (IgG
1
)
Myeloperoxidase,    >118 kDa    Neutrophil and monocyte Mouse anti-human  2 µg/ml
MPO                                           primary (azurophilic)        myeloperoxidase, a mixture 
                                                   granules                             of six clones (IgG
1
)
Human neutrophil 40 kDa        Neutrophil secondary        Mouse anti-human   10 µg/ml
lipocalin, HNL                           (specifi c) granules              neutrophil lipocalin,
                                                                                             a mixture of six clones (IgG
1
)
* Antibodies were provided by Dr. Christer Peterson, Pharmacia & Upjohn Diagnostics AB, Uppsala, 
Sweden.
4.8. Control experiments (Study I)
4.8.1. Performance characteristics
Performance characteristics (precision, measuring range, sensitivity) were examined in four 
assays (ECP, EPO, MPO, and HNL) in relation to total sputum method, and compared 
with results relating to serum. Effects of repeated freezing and thawing were studied in 
relation to total sputum MPO levels. Seven DTT- and CTAB-treated sputum samples were 
analysed for MPO immediately after treatment, and after one, two or three freezing and 
thawing cycles.
4.8.2. Dilution
To determine the effects of DTT and CTAB on assays for total ECP, a standard curve was 
prepared using DTT and CTAB and compared with the curve prepared using physiologi-
cal saline. Experiments relating to EPO, MPO, and HNL were performed analogously.
The effect of sample dilution was determined by assaying the same sputum sample at dif-
ferent dilutions. All dilutions gave results within the measuring (working) range of the 
relevant assay. Marker concentrations were measured and corrected for dilution to deter-
mine whether dilution alone affected the mediator value obtained.
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4.8.3. Recovery
Recovery of ECP was determined by adding stock solutions of ECP standards to three 
sputum samples pre-incubated with DTT and CTAB. Original sputum samples and samp-
les to which stock solution had been added were assayed simultaneously, and recoveries 
were calculated. Experiments for EPO, MPO and HNL were performed analogously.
4.8.4. Reproducibility of markers levels and differential cell counts 
          in sputum
To evaluate within-subject variability relating to sputum induction, induced sputum 
samples were twice obtained from 16 subjects, one-week apart. The group included 12 
healthy subjects (mean age 44 years, 11 of whom were female) with normal PEF values, 
and four asthma patients (mean age 42 years, three of whom were female) with a mean 
FEV
1
 of 75.5% of that predicted. Sputum samples were analysed using both the reference 
method [154] and the method under investigation (Study I).
The reproducibility of sputum differential cell counts was determined using 10 cytocent-
rifuged sputum preparations stained using the MGG method. Repeated-measures analysis 
of variance was undertaken, with calculation of the within-examiner and between-exami-
ners coeffi cients of reliability (R).
4.9. Statistical analysis (Studies I, III to V)
Data were analysed using Astute Statistics Add-in and SAS software. Generally, data 
are expressed as means and standard deviation (SD), or medians and ranges. Medians and 
ranges were preferred for infl ammation markers, because values below the lowest standard 
points were regularly observed. All results were analysed. Values below the lowest stan-
dard point were given the numerical value of that. As the distributions of results of several 
assays (of all markers of infl ammation) were roughly lognormal, logarithmic values were 
used for statistical evaluation, i.e. geometric means were compared. In other cases, loga-
rithmic transformation was not used.
To determine sensitivities and specifi cities of various tests, reference (normal) values 
were calculated. Since different sputum-processing methods were used, normal values for 
sputum markers varied from study to study. For all assays of sputum markers, 95% ranges 
(means ± 2 SDs) were obtained relating to the healthy control groups. In other cases, refe-
rence ranges previously determined in our laboratory, or obtained from the reagent manu-
facturer or from the literature were considered more appropriate, as numbers of subjects in 
control groups were low.
Because the variable was continuous, and selection of a cut-off point was arbitrary, diag-
nostic accuracy was determined by generating a receiver-operating characteristic (ROC) 
curve for each test [3, 67]. Areas under curves (AUCs) were compared using the method 
of Hanley and McNeil [67, 68].
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Differences between groups were analysed using the non-parametric Wilcoxon-Mann-
Whitney U-test or Mann-Whitney test (Study V). Values of p < 0.05 were considered 
to indicate signifi cance. In relation to comparisons between groups, Student’s t-test and 
Wilcoxon’s rank-sum test were used (Studies IV and V). Two-tailed p-values below 0.05 
were considered to indicate signifi cance. Signifi cances of differences between more than 
two study groups were fi rst analysed using Kruskal-Wallis one-way analysis by ranks 
(Study I). When signifi cant differences between groups were observed, intergroup compa-
risons were made using the Wilcoxon-Mann-Whitney U-test (Study I). In assessing corre-
lations between variables (e.g. lung-function data, differential cell counts, concentrations 
of infl ammation markers) the Spearman rank-order test was used (Studies I, III to V). Sig-
nifi cance was accepted at the 95% level.
Reproducibility of marker measurements was expressed via an intraclass correlation coeffi -
cient (R
i
) [105] using log-transformed values, and was graphically reported as suggested 
by Bland and Altman [13]. Values above 0.75 indicate high reliability (Study I).
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5. RESULTS
5.1. Sputum induction (Studies I to V)
Several sputum induction methods were carried out during the course of the study. Out-
puts, ranges of particle sizes and concentrations of inhaled saline varied between the nebu-
lizers (Table 8). However, no signifi cant differences were found between the two nebuli-
zers (Omron U1, SpiraUltra) as assessed by change in PEF, success rate, cell viability or 
squamous-cell contamination (unpublished data).
Table 8. Nebulizers used in Studies I to V
Type             Manufacturer       Output (ml/min)    AMMD* (µm)      NaCl Conc. (%) Study 
Omron U1    Omron,                 0.25      1 - 7                           3 I and II
                     Germany
SpiraUltra     Hengityshoito-      0.60      1.1 - 2.2                     5 III-V
                     keskus, Finland            (of 60% particles)
*AMMD = aerodynamic mass median diameter
The sputum-induction procedure was found to be safe, even without pre-treatment with 
a β
2
-agonist. No subject in any study required treatment with a bronchodilator following 
induction. The mean fall in PEF values during sputum induction was only 1.3% from 
baseline in Study I (unpublished data).
The effect of sputum induction on PEF was studied in the Skin and Allergy Hospital by 
obtaining induced sputum samples without pre-treatment from 200 patients with asthma 
or suspected of having asthma. PEF values were measured before and after inhalation of 
hypertonic saline. A fall in PEF values was noticed in 50% of patients. The mean fall in 
PEF was 5%, the maximum 20% (unpublished data).
Table 9. Success rate of sputum induction
 Study               Healthy subjects                Patients 
 I                        81% (42/52)                        100% (10/10) respiratory infection 
                                                                     100% (8/8) COPD 
                                                                     100% (17/17) asthma#  
 III*                   100% (10/10)                      100% (23/23) early asthma 
                                                                     100% (19/19) chronic asthma  
 IV                     70% (23/30)                        73% (58/80) baseline 
                                                                     59% (24/41) after BUD treatment 
                                                                     70% (27/39) after TER treatment  
 V                      67% (10/15)                        86% (12/14) baseline 
                                                                     86% (12/14) after treatment  
 Ref. 172           92% (49/53)                        85% (11/13) prolonged cough with asthma 
                                                                     90% (62/69) prolonged cough without asthma 
* Production of an adequate sputum sample was an inclusion criterion.
# A subgroup of 17 patients. The success rate in the group overall was 84% [171].
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A sputum sample was considered adequate, and was included in the study, if it contained 
macrophages or ciliated epithelial cells. In general, the success rate of induction in respect 
with adequacy was good but there was variation from study to study (Table 9). After tre-
atment the success rate in relation to sputum induction decreased (Study IV). Salivary 
contamination was assessed in terms of numbers of squamous epithelial cells. The exclu-
sion limit was 80% in differential cell counts [194]. The median percentage of squamous 
epithelial cell contamination in all 77 subjects in Study I was 5.4% (range 0 to 72%). Cell 
viability, when investigated, was over 80% in all samples included in the evaluation.
5.2. Sputum-processing method for clinical use (Study I)
5.2.1. Correlations between total and released marker concentrations
Correlations between total and released marker concentrations were excellent in relation to 
ECP (r
s 
= 0.80, p < 0.0001) and HNL (r
s 
= 0.87, p < 0.0001), good in relation to MPO 
(r
s 
= 0.71, p < 0.0001) and moderate in relation to EPO (r
s 
= 0.49, p < 0.0001) when 
all study groups were evaluated. Unsurprisingly, correlations varied between study groups 
and markers. For example, total EPO concentrations correlated signifi cantly with released 
EPO concentrations in the asthma and COPD groups but not in patients with respiratory 
infection or healthy individuals (Fig. 3). In contrast, strong correlations in respect of total 
and released ECP and HNL markers were observed in all groups.
Figure 3. Correlation between total and released EPO levels. All values are expressed as 
µg/L. Because of the number of undetectable values some correlations relating to healthy 
individuals and patients with respiratory infection are not given. Results for some patients 
are missing because of limited volumes of sputum supernatants. Symbols: Healthy indivi-
dual: open triangle, respiratory infection: open box, chronic obstructive pulmonary disease 
(COPD): closed circle, asthma: closed box.
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5.2.2. Association between total and released marker levels 
          and sputum cells 
In patients with asthma and COPD there were no signifi cant differences in mean pro-
portions of sputum eosinophils but in both groups there were more eosinophils than in 
patients with respiratory infection or healthy individuals (Table 10). Patients with respira-
tory infection and COPD had signifi cantly higher proportions of sputum neutrophils than 
asthma patients or healthy individuals (Table 10). 
Table 10. Cytospin cell counts in induced sputum. The method of sputum examination described 
by Pizzichini et al. [153] was used.
Characteristic Healthy            Infection            COPD  Asthma  P value* 
             n = 42                 n = 10                n = 8 n = 17
Total cells  1.91                    2.82                  1.16  0.78  0.055
(x 106)#   0.03 - 12.9         0.16 - 5.86         0.34 - 3.96 0.01 - 3.60
Absolute eosinophils  10                      23                      55  49  0.0001
(x 103)#   0 - 120                0 - 88                0 - 210 0 - 269
Absolute neutrophils  925                   2318                  1031  385  0.0059
(x 103)#   1 - 9159           123 - 5040         201 - 3378 3 - 1556
Eosinophils   0.31                    0.80                  3.57  17.84  < 0.0001
(%)        0.0 - 4.9             0.0 - 2.3             0.0 - 7.9 0.0 - 89.5
Neutrophils  37.9                    82.9                  73.4  45.2  < 0.0001
(%)        3.0 - 87.5          68.4 - 92.4         46.3 - 90.5 3.1 - 81.9
Data expressed as median and range. #The result obtained per sample. *Kruskal-Wallis test
Total and released ECP and EPO levels correlated signifi cantly with eosinophil percenta-
ges (r
s
 = 0.62, p < 0.0001 for total ECP; r
s
 = 0.52, p < 0.0001 for released ECP; r
s
 = 
0.69, p < 0.0001 for total EPO; r
s
 = 0.67, p < 0.0001 for released EPO) when all study 
groups were included. Similarly, total and released HNL and MPO levels correlated with 
neutrophil percentages (r
s
 = 0.65, p < 0.0001 for total HNL; r
s
 = 0.52, p < 0.0001 for 
released HNL; r
s
 = 0.56, p < 0.0001 for total MPO; r
s
 = 0.56, p < 0.0001 for released 
MPO). Degree of correlation depended, however, on study group and marker. For instance 
signifi cant correlations were found between eosinophil percentages and total ECP and EPO 
concentrations in asthmatics but not in patients with COPD or healthy individuals.
5.2.3. Reference values
Reference (normal) values for total sputum markers were calculated (Table 11) (unpub-
lished data). Sputum was processed as in Study I (details on page 49). For all markers, 
95% (mean ± 2SD) ranges were obtained for the control group. Log-transformed values 
were used in calculations. The control group (n = 35) consisted of fi ve atopic and 30 non-
atopic subjects, with a mean age of 42.4 years (range 29 to 61 years). There were 32 non-
smokers, two former-smokers and one smoker in the control group.
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Table 11. Reference values for total sputum markers
 Assay                                Reference range                                         
 ECP                                   < 2500 µg/L
 EPO                                  < 400 µg/L
 MPO                                 < 1200 µg/L
 HNL                                 < 19300 µg/L
5.3. Immunocytochemical detection of intracellular 
       markers (Study II, unpublished)
Cytocentrifuged samples were processed using various fi xation and permeabilization met-
hods (see page 40), then incubated with various monoclonal antibodies (see page 40). Cha-
racteristics (including cell structure, nuclear staining, intensity of immunoreaction, penet-
ration of antibody, antigen leakage and reproducibility of method) were graded using an 
arbitrary scale. Parameters in relation to structure were cell size, granularity and shape of 
polymorphic nucleus. Results are summarized in Figures 4 to 6 and in Table 12.
General structures of unfi xed cells and cells fi xed with organic agents were poor (Fig. 5a - d). 
Nuclear staining with Mayer’s haematoxylin was weak and structural preservation was impro-
per (Fig. 5a - d). When the fi xative contained an aldehyde as a crosslinking reagent, different 
leukocyte types could easily be identifi ed on the basis of moderately well stained nuclei (Fig. 
5e - f). With IntraPrep, results were similar to those obtained using fi xatives containing an 
aldehyde (Fig. 6a). Structural preservation and nuclear staining with Mayer’s haematoxylin was 
best with OPF, which also preserved the granularity of the cell (Fig. 6b - f).
Immunolabelling varied from weak to moderate in unfi xed cell samples (Fig. 5a). Immu-
noreactivity was very weak and cytoplasmic, or cells remained totally negative when samp-
les were fi xed with organic solvents (Fig. 5b - c), except that intensities of MPO-positive 
neutrophils in acetone-fi xed samples were substantial (Fig 5d). Immunolabelling of cells 
fi xed with aldehydes varied from good to excellent, depending on the method used (Fig.5e 
- f). However, immunolabelling was uneven, with strong peripheral staining. Eosinophil 
and neutrophil granules were occasionally positive with all aldehyde-containing fi xatives. 
In OPF-treated samples, immunoreaction was evenly distributed throughout the cell, 
irrespective of the antibody used, indicating that antibodies had penetrated cellular and 
granular membranes (Fig. 6b - f). Granules in eosinophils were always visible and mar-
kedly positive. No antigen leakage or diffusion was visible in cells fi xed with OPF or 
IntraPrep. A positively stained area adjacent to cells was occasionally observed in unfi xed 
cells, indicating leakage of antigen (Fig. 4a).
Intersample reproducibility was excellent with cells fi xed and permeabilized using the 
two commercial reagents (OPF and IntraPrep), PLP, formaldehyde and acetone. Unfi xed 
and methanol-fi xed cells stained unevenly within samples. Some cells were positive, others 
remained totally negative. There was also variation between cells in samples treated with 
crosslinking fi xatives but containing no agent affecting permeability. Some cells were 
stained throughout, others exhibited peripheral staining as described above.
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No unspecifi c background reaction was seen in any cell in control samples. EG2-positive 
eosinophils and EG2-immunolabelled neutrophils were, however, seen with all fi xatives 
studied (Fig. 6d). There was no difference in results obtained with cytospin samples 
frozen prior to fi xation-permeabilization treatment and with those treated immediately.
Figure 4. Cell samples stained using the May-Grünwald-Giemsa (MGG) method.
a: BAL-fl uid from patient with asthma. Original magnifi cation 40 x.
b: Sputum from patient with asthma. Original magnifi cation 100 x.
Symbols: N, neutrophil; E, eosinophil; M, macrophage; L, lymphocyte.
Figure 5. Fixatives containing organic solvents or aldehyde-based fi xatives. 
a: Unfi xed sputum cells from a patient with asthma. Immunolabelling with monoclonal 
antibody to EPO. Because of poor structural preservation and faint nuclear staining diffe-
rent cell types cannot be identifi ed. The EPO-positive cell (Eo) is probably an eosinophil. 
Note leakage of antigen. Original magnifi cation 40 x.
b: BAL cells (from a patient with prolonged cough) fi xed with methanol at room tempe-
rature and immunolabelled with monoclonal antibodies to MPO. Cell structure is gene-
rally poor, and cell membranes appear damaged. Note the two weakly MPO-positive neut-
rophils (Ne). Original magnifi cation 40 x.
c: Sputum cells from a healthy individual fi xed with acetone and immunolabelled with 
monoclonal antibodies to HNL. Structure of neutrophils has been badly damaged and lea-
kage of HNL from neutrophils is obvious, and has led to unspecifi c background. Nuclear 
staining is weak and uneven. Original magnifi cation 20 x.
d: BAL cells (from a patient with chronic bronchitis) fi xed with acetone and immunola-
belled with MPO antibodies. Cells structures are generally acceptable but nuclear staining 
is weak. Two neutrophils have been relatively strongly stained after immunolabelling with 
MPO antibody. Unspecifi c background is visible. Original magnifi cation 100 x.
e: BAL cells (from a patient with asthma) fi xed with 10% FA and immunolabelled with 
monoclonal antibody to EPO. Cell structures are well preserved but nuclear staining is 
weak. An eosinophil is brightly stained but the staining appears uneven. Stain is most 
intensive at the periphery of the cell. Original magnifi cation 1000 x.
f: BAL cells (from a patient with asthma) fi xed with PLP and immunostained with 
monoclonal antibody to EPO. Cell structures and intensity of immunolabelling are similar 
to those in Fig. 5e. Cell membrane is more intensively stained than the interior. Original 
magnifi cation 100 x.
Symbols: N, neutrophil; E, eosinophil; M, macrophage; L, lymphocyte.
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6a 6b
6c 6d
6e 6f
Figure 6. Fixatives containing agents affecting permeability. Cellular preservation was 
best, and immunostaining most intensive and even, when OPF was used as fi xative. Note 
intense nuclear staining, which facilitates identifi cation of different cell types.
a: BAL cells (from patient with prolonged cough) fi xed with IntraPrep and immunos-
tained with monoclonal antibody to MPO. Different cell types can be identifi ed after stai-
ning with Mayer’s haematoxylin. No unspecifi c background staining or leakage of antigen 
is visible. Original magnifi cation 100 x.
b: BAL cells (from a patient with asthma) fi xed with OPF and immunostained with 
monoclonal antibody to EPO. Original magnifi cation 20 x.
c: Same as previous sample but higher magnifi cation. Original magnifi cation 100 x.
d: Sputum cells fi xed with OPF and immunostained with monoclonal antibody, EG2 clone 
to ECP. Sputum from a healthy individual. Original magnifi cation 100 x.
e: BAL cells (from patient with chronic bronchitis) fi xed with OPF and immunostained 
with monoclonal antibody to MPO. Original magnifi cation 100 x.
f: Sputum cells fi xed with OPF and immunostained with monoclonal antibodies to HNL. 
Sputum from a patient with COPD. Original magnifi cation 40 x.
Symbols: N, neutrophil; E, eosinophil; M, macrophage; L, lymphocyte.
51
T
ab
le
 1
2.
 C
ha
ra
ct
er
is
tic
s 
of
 A
PA
A
P-
st
ai
ne
d 
eo
si
no
ph
ils
 (
an
tib
od
ie
s 
to
 E
C
P 
an
d 
E
PO
) 
an
d 
ne
ut
ro
ph
ils
 (
an
tib
od
ie
s 
to
 H
N
L
 a
nd
 M
P
O
) 
in
sp
ut
um
 (
n 
=
 1
3)
 a
nd
 B
A
L
 (
n 
=
 4
) 
sa
m
pl
es
.
C
h
ar
ac
te
ri
st
ic
U
nf
ix
ed
A
ce
to
ne
M
et
h
an
ol
,
R
T
.
M
et
h
an
ol
,
-2
0 
C
P
L
P
10
%
 F
A
In
tr
aP
re
p
P
er
m
ea
fi
x
C
el
l s
tr
uc
tu
re
Po
or
Po
or
Po
or
A
cc
ep
ta
bl
e
G
oo
d
G
oo
d
E
xc
el
le
nt
E
xc
el
le
nt
N
uc
le
ar
 s
ta
in
in
g
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Im
m
un
or
ea
ct
iv
ity
+
+
+
+
+
+
+
 (
M
P
O
)
+ 
(O
th
er
s)
+
+
+
 (
M
PO
)
+ 
(O
th
er
s)
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Pe
ne
tr
at
io
n
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
L
ea
ka
ge
 (d
if
fu
si
on
)
- 
- 
-/
 -
 -
- 
- 
- 
-
- 
- 
- 
-
- 
- 
- 
-
- 
- 
-
- 
- 
-
-
-
R
ep
ro
du
ci
bi
lit
y
Po
or
E
xc
el
le
nt
Po
or
Po
or
E
xc
el
le
nt
E
xc
el
le
nt
E
xc
el
le
nt
E
xc
el
le
nt
Sc
al
es
 r
el
at
in
g 
to
 c
ha
ra
ct
er
is
ti
cs
:
C
el
l s
tr
uc
tu
re
: e
xc
el
le
nt
, g
oo
d,
 a
cc
ep
ta
bl
e,
 p
oo
r
N
uc
le
ar
 s
ta
in
in
g:
 +
+
+
+
 (
ex
ce
lle
nt
),
 +
+
+
 (
go
od
),
 +
+
 (
ac
ce
pt
ab
le
),
 +
 (
po
or
)
Im
m
un
or
ea
ct
iv
ity
: +
+
+
+
+
 (
th
ro
ug
h 
ce
ll 
m
em
br
an
e,
 e
xc
el
le
nt
),
 +
+
+
+
 (
st
ro
ng
),
 +
+
+
 (
in
te
rm
ed
ia
te
),
 +
+
 (
fa
in
t)
, +
 (
po
or
)
Pe
ne
tr
at
io
n:
 +
+
+
+
+
 (
th
ro
ug
h 
ce
ll 
m
em
br
an
e)
, +
+
+
+
 (
st
ro
ng
),
 +
+
+
 (
in
te
rm
ed
ia
te
),
 +
+
 (
fa
in
t)
, +
 (
po
or
),
 0
 (
no
 v
is
ib
le
 im
m
un
or
ea
ct
iv
ity
, n
o 
re
ac
tio
n)
L
ea
ka
ge
 (
di
ff
us
io
n)
: -
--
--
 (
w
or
st
),
 -
--
- 
(s
tr
on
g)
, -
--
 (
in
te
rm
ed
ia
te
),
 -
- 
(s
om
e 
le
ak
ag
e)
, -
 (
no
 v
is
ib
le
 le
ak
ag
e)
R
ep
ro
du
ci
bi
lit
y:
 e
xc
el
le
nt
 (
al
l t
ar
ge
t c
el
ls
 s
ta
in
ed
),
 p
oo
r 
(s
om
e 
ta
rg
et
 c
el
ls
 s
ta
in
ed
)
52
5.4. Cell-specifi city of eosinophilic and neutrophilic 
       infl ammation markers (Study II)
Sputum and BAL-fl uid cells were treated using Ortho Permeafi x. This was found to be 
the optimum method for fi xation and permeabilization of the cell samples in question. 
Eosinophils (stained with anti-EPO or EG1/EG2 antibodies) and neutrophils (stained with 
anti-HNL or anti-MPO antibodies) appeared bright red on the slides. All other cells 
remained blue (counterstained with haemotoxylin) and recognizable. Eosinophils remained 
unstained when anti-HNL was used, and neutrophils remained unstained when anti-EPO 
was used. Granules in eosinophils and neutrophils were visible, and stained very bright 
red, indicating that antibodies had penetrated cell and granule membranes. Cells stained 
by neither anti-EPO nor anti-HNL included lymphocytes, squamous epithelial cells, and 
ciliated epithelial cells. Macrophages positive for anti-EPO and anti-HNL were occasion-
ally seen among sputum-sample and BAL-fl uid cells.
When antibodies against ECP (EG2 and EG1) were used, eosinophils were always posi-
tive. However, neutrophils were frequently positive in sputum and BAL samples (Fig. 6d). 
When anti-MPO antibodies were used as a primary antibody, all cells except neutrophils 
remained unstained. In one patient with asthma, monocytes and neutrophils were positive 
for MPO antibodies in her sputum and BAL samples. Monocytes were seldom found in 
sputum or BAL samples. No background reaction was seen in any cell in negative control 
samples.
On average 8 600 neutrophils (range 11 to 40 700) and 695 eosinophils (range 13 to 
7 000) from 17 patients and healthy individuals were examined. Cell profi les on standard 
MGG-stained slides were compared with profi les on slides counterstained with Mayer’s 
haematoxylin after immunostaining. Percentages of sputum and BAL-fl uid cells stained 
using anti-EPO were higher than percentages of eosinophils observed using conventional 
MGG-staining (MGG 5.9% versus anti-EPO 6.7%, p = 0.0015, Student’s t-test). Analo-
gous observations were made for neutrophils using anti-HNL (MGG 49.3% versus anti-
HNL 52.3%, p = 0.039, Student’s t-test). Percentages of other cell types on immunos-
tained slides were not signifi cantly different from percentages obtained after MGG stai-
ning and differential counting (data not shown).
5.5. Sensitivity and specifi city of infl ammation marker
       assays (Studies III to V)
Sensitivity and specifi city were calculated for several laboratory tests. By defi nition, sensi-
tivity is the proportion of true positives correctly identifi ed and is 1 - the false-negative 
rate. Specifi city is the proportion of true negatives correctly identifi ed and is 1 - the false-
positive rate. Reference values were needed and for some analyses were calculated from 
control-group data.
Study III. In early or suspected asthma, sensitivities for various combinations of tests were 
higher than those for individual tests (Table 13). The histamine-challenge test, generally 
regarded as a good diagnostic aid, had a sensitivity of 48%. Determination of PEF and 
histamine challenge together had a 65% sensitivity. Supplementation of this combination 
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with sputum examination (eosinophils and ECP) led to a 78% sensitivity. Sensitivities 
relating to sputum eosinophils, and ECP and EPX assays were similar, 35 to 39% in the 
early or suspected asthma group, 44 to 79% in chronic asthma. Sensitivity reached 83% 
when all tests were combined.
Study IV. Lung-function results were excluded when sensitivities and specifi cities were 
examined, since an abnormal lung function measurement was an inclusion criterion. In 
this study, sensitivities of various combinations of tests were higher than those of indivi-
dual tests (Table 13). The use of two ECP measurements (serum and sputum) resulted in 
a sensitivity of 53%. The sensitivity of each ECP test individually was 33%. When all 
laboratory tests were combined, sensitivity was 58%.
Table 13. Sensitivities and specifi cities of laboratory tests and combinations of tests in Studies 
III and IV. Reference ranges marked* were calculated from control-group data. Sensitivities and 
specifi cities in both studies were calculated from data relating to patients with early or suspected 
asthma (Study III) and to patients with newly detected, mostly mild, asthma (Study IV).
Test or combination of tests                     Sensitivity %          Sensitivity % Specifi city % 
                                                                    (Study III)               (Study IV) (Study IV)  
PEF monitoring                                           39                            - -
Bronchial reactivity measured by                 48                            - -
   means of histamine-challenge tests
Blood eosinophils (109/L)                             26                            33 93
Blood neutrophils (109/L)                             N.D.                        3 100
Serum ECP (µg/L)                                        30                            33 97
Serum EPX (µg/L)                                       26                            N.D. N.D.
Serum MPO (µg/L)                                      9                              23 93
Sputum eosinophils (arbitrary)                     35                            17 100
Sputum neutrophils (arbitrary)                     10                            0 100
Sputum ECP (µg/L)*                                   35                            33 100
Sputum EPX (µg/L)*                                   39                            N.D. N.D.
Sputum MPO (µg/L)*                                  13                            N.D. N.D.
Urine EPX/creatinine (µg/mmol)*               39                            6 97
                                                                                    
Sputum ECP + serum ECP                          44                            53 96
Sputum ECP + serum MPO                         40                            47 91
Sputum ECP + sputum eosinophils              43                            42 100
Sputum ECP + blood eosinophils                 40                            40 91
Serum ECP + blood eosinophils                   35                            38 93
                                                                                                      
All tests                                                       83                            58 83
N.D.: not determined
Receiver-operating characteristic (ROC) curves for ECP in sputum and blood were exa-
mined (Fig. 7). Areas under curves (AUCs) for sputum and serum ECP levels indicate that 
assay for sputum ECP (AUC = 0.78) was more sensitive and specifi c than assay for serum 
ECP (AUC = 0.62) in differentiating between patients with newly detected asthma and 
control subjects.
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Figure 7. ROC curves for serum and sputum ECP (Study IV). The further to the “north-
west” a plot lies the more accurate values it represents.
5.6. Differential diagnosis (Studies I, IV and V)
In all of the studies, signifi cant differences were observed in relation to both laboratory 
and lung-function parameters between healthy controls and patients in the various groups. 
In general, patients with asthma had higher sputum ECP levels than controls (p = 0.0002, 
Study IV; p = 0.018, Study V). The difference in sputum ECP levels was always signifi -
cant, and even increased after adjustment for sputum albumin (p = 0.001) (Study V). No 
other signifi cant differences in laboratory parameters were observed between patients and 
controls. Sputum ECP results are summarized in Table 14.
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Table 14. Sputum ECP (µg/L) results in different study groups. 
Values expressed as medians and ranges.
Study                          Control subjects Patients                              P value* 
Study I                       572 (68 - 2706)            Asthma   2485 (386 - 69940)   < 0.0001 
Total markers                                                   COPD 5840 (681 - 15400)    0.0002
                                                                        Respiratory infection 4937 (397 - 21160)    0.0004
Study I                       140 (19 - 985)              Asthma   748 (60 - 5647)         0.008   
Released markers                                              COPD 2104 (88 - 3726)        0.001
                                                                        Respiratory infection 1329 (67 – 14202)     < 0.0001
Study IV                     117 (14 - 702)              Budesonide-treated    490 (38 - 35900)       < 0.005  
Total markers                                                   patients
                                                                        Terbutaline-treated 507 (37 - 20400)        < 0.005 
                                                                        patients
Study V                      140 (22 - 556)              Asthma 591 (18 - 3992)          0.018
Total markers
*Difference between controls and patients at baseline. Mann-Whitney test (Study IV), Dunett’s two-
tailed t-test (Study V) and the Kruskal-Wallis (Study I) test were used.
In Study IV, patients were divided into subgroups in accordance with the severity of their 
asthma. Sixty-one of 80 patients (76%) were considered to have mild asthma and 19 (24%) 
moderate or severe asthma, on the basis of case histories, lung-function results and symp-
tom scores. At baseline, moderate or severe asthmatics had higher sputum ECP levels (p 
= 0.04) than mild asthmatics, and higher numbers of eosinophils in sputum (p = 0.04).
In Study I, two sputum-processing methods were examined. Four biochemical markers 
(ECP, EPO, MPO and HNL) were measured in sputum sample supernatant (released mar-
kers) and in sputum sample lysate (total markers). Differential cell counts were undertaken 
using cell pellets. In patients with asthma and COPD there were no signifi cant differences 
in mean percentages of sputum eosinophils, though the proportion of sputum eosinophils 
was higher in both groups than in patients with respiratory infection or healthy subjects.
Total ECP levels were highest in COPD patients, next highest in patients with respiratory 
infection. Highest values for total EPO were also observed in COPD patients. There were 
no signifi cant differences between patients with respiratory infection and COPD patients 
in respect of sputum neutrophils or concentrations of neutrophil-derived markers. Patie-
nts with respiratory infection had signifi cantly higher proportions of sputum neutrophils 
and higher concentrations of total HNL and MPO than healthy subjects and patients with 
asthma. COPD patients had higher concentrations of total and released HNL and MPO 
than patients with asthma. 
The ratio of eosinophils to neutrophils was calculated as the ratio of total ECP to total 
MPO (Fig. 8). A signifi cant difference in ratio of total ECP/total MPO was observed bet-
ween the four study groups (p = 0.0002, Kruskal-Wallis test) although there were over-
laps between results for the different groups. Further analysis demonstrated that this ratio 
differed signifi cantly between healthy subjects and the other three groups (asthma p = 
0.005, COPD p = 0.01, respiratory infection p = 0.01), between COPD and asthma patie-
nts (p = 0.005), and between patients with respiratory infection and asthma (p = 0.003). 
No difference in total ECP to total MPO ratio was observed between patients with respi-
ratory infection and COPD.
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Figure 8. Ratios of total ECP to total MPO in four study groups
5.7. Effect of therapy on infl ammation markers 
      (Studies IV and V)
The effects of anti-infl ammatory treatment on markers of infl ammation and lung-function 
parameters were examined in both adults and children. Blood, sputum and/or urine samp-
les for marker assay were taken before and after each treatment period.
Study IV. Patients were randomised into two treatment groups. One group received an 
inhaled steroid (budesonide, BUD) for six weeks, the other an inhaled sympatomimetic 
(terbutaline, TER) for six weeks followed by two weeks of inhaled steroid (BUD). At base-
line, the two patient groups were similar in relation to all clinical parameters examined 
(Table 4, page 40). In the BUD group, patients’ condition improved signifi cantly after 
six weeks of treatment, as judged by symptom scores (p = 0.039), morning PEF values 
(p = 0.0012), blood eosinophil counts (p = 0.0002) and sputum ECP concentrations (p = 
0.0118) (Fig. 9). In the atopic subgroup, serum ECP levels (p = 0.035) also fell. In the 
TER group, no parameter changed signifi cantly (p > 0.05). When the terbutaline patients 
were switched for two weeks to BUD medication, their conditions improved in a similar 
way to the conditions of patients treated with BUD from the beginning. Serum ECP levels 
decreased in both groups during steroid treatment, but the changes were not signifi cant 
(p = 0.074 for the BUD group, p = 0.056 for the TER group).
Control
subjects
Respiratory
infection
COPD Asthma
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Figure 9. Effect of treatment on sputum ECP (IV). Patients with newly detected asthma 
were treated with inhaled budesonide (BUD, n = 39) or inhaled terbutaline (TER, n = 
41) for six weeks. Patients in the TER group then received inhaled BUD for two weeks. 
A non-atopic, non-smoker control group (n = 30) was also examined.
Study V. Asthmatic children were treated with inhaled steroids at high doses for one 
month, and with half the high dose for fi ve months. Treatment was then changed to inha-
led nedocromil, and this treatment was continued for another six months. Signifi cant cli-
nical improvement, as judged by increases in both PEF and PD
15
 values and decreases in 
symptom scores, was noted during steroid treatment (Fig. 10). The clinical improvements 
were accompanied by decreases in sputum ECP but there were no further changes during 
nedocromil therapy (Fig. 10). After adjustment for sputum albumin, decreases in sputum 
ECP levels were even more signifi cant (p = 0.017). During steroid treatment blood eosi-
nophil counts decreased signifi cantly (p = 0.040), but serum ECP levels did not fall. No 
further changes in these parameters were noted during treatment with nedocromil.
0
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Figure 10. A) Sputum ECP levels (median, µg/L) and B) PEF values (median, % of pre-
dicted) in 12 children with newly detected asthma before and after treatment for one and 
six months with inhaled steroid (budesonide), and with inhaled nedocromil for a further 
six months.
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5.8. Control experiments (Study I)
5.8.1. Performance characteristics
The assays for ECP, EPO, MPO and HNL were originally developed for use of serum, 
according to the manufacturer. In Study I, concentrations of mediators were determined 
in sputum samples that had been treated different ways. Assay characteristics for the app-
lication of total sputum method are summarized in Table 15 (unpublished data). Intra-
assay coeffi cients of variation differed between assays (mean 4.1%, range from 38.9% at 
very low levels of EPO to zero at high levels). The detection limit (sensitivity) was defi ned 
as the concentration given by the counts three standard deviations above that of a zero 
sample. There were no signifi cant differences between serum and sputum applications in 
any assay parameter studied.
Table 15. Assay characteristics for sputum application (for total markers) (Study I). The fi gures 
are adjusted for 10-fold dilution during processing treatment.
Assay           Measurement         Sensitivity                 Coeffi cient of variation (%)  
                    range                                                          Intra-assay#
                    (µg/L)                        (µg/L)                 Mean            Range
ECP             20 - 2000                 < 14                       2.1 0.0 - 6.5
EPO             5 - 2000                   < 5                         5.8 0.0 - 38.9
MPO            80 - 10000               < 80                       5.3 0.1 - 23.5
HNL            200 - 6000               < 170                     3.1 0.1 - 10.5
# Two replicates (n = 56 - 85). Data expressed as means and ranges.
The effects of freezing and thawing were determined in relation to sputum MPO, since 
low levels of released sputum MPO have been reported for DTT-treated samples after free-
zing (C. Peterson, personal communication). No statistically signifi cant differences were 
observed (Table 16) when samples were treated with DTT and CTAB prior to freezing.
Table 16. Effects of freezing and thawing on sputum MPO levels (n = 7). Sputum treated with 
DTT and CTAB.
 Mean (µg/L) Range (µg/L) P value* 
Baseline 4534 1060 – 15600 
Once frozen and thawed 4274 1145 – 15000 0.89
Twice frozen and thawed 4253 1215 – 13650 0.34
Thrice frozen and thawed 4549 1145 – 16250 0.34
*Wilcoxon test
5.8.2. Dilution
The effects of DTT and CTAB were studied by treating reference proteins (ECP, EPO, 
MPO and HNL) with the two agents. A standard curve relating to DTT and CTAB treat-
ment was compared with the curve relating to saline treatment. The nature of treatment 
did not affect the shapes of standard curves (unpublished data). The results indicate that 
treatment with a combination of DTT and CTAB had no effect on assay results. 
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A sputum sample was assayed at different dilutions, and results were compared to deter-
mine whether dilution alone affected results. Values for total ECP are shown in Table 17. 
Values of the other three total markers were also appropriate and as expected [129].
Table 17. Data are expressed as percentages of obtained concentration/expected concentration of total 
ECP on assay of four sputum samples serially diluted [129].
Sample                                           1                         2                        3 4 
Original ECP (µg/L)                     139                     17.3                    127 115
                                                                                                                
Diluted 1/2                                   96%                    83%                  93% 109%
Diluted 1/4                                   92%                    93%                  93% 105%
Diluted 1/8                                   93%                   104%                 89% 102%
Diluted 1/16                                102%                   N.a.                   89% 101%
N.a. = Not available
5.8.3. Recovery
Assays for total mediator were performed in sputum samples to which known amounts 
of the mediator had been added after treatment with DTT and CTAB and for released 
mediator in sputum samples to which known amounts of the mediator had been added 
after DTT treatment. In general, recoveries of total and released mediator from such samp-
les were good (between 80% and 120%) (Table 18). The results indicate that the proteins 
concerned were not bound in pre-treated sputum samples.
Table 18. Recoveries of total and released mediator from sputum samples (Study I)
Mediator                                              Recovery (%)  
                                                   Total             Released
ECP                                      102.1 ± 5.5                 101.2 ± 4.5
EPO                                      96.6 ± 12.9                 100.4 ± 22.5
HNL                                     100.5 ± 6.4                 98.5 ± 4.9
MPO                                     99.7 ± 6.3                   102.7 ± 18.7
Data expressed as means ± SDs.
5.8.4. Reproducibility of assays for markers and of differential 
          cell counts in sputum
Within-subject variability and the reproducibility of assay results in relation to total and 
released markers in sputum were determined in 16 subjects from each of whom two indu-
ced sputum samples had been obtained, a week apart. Results are summarized in Table 
19, and in Figure 11 (total ECP and total MPO) as suggested by Bland and Altman [13]. 
Reproducibility was generally high in relation to ECP, MPO and HNL, low in relation to 
EPO. Results were similar for assays of both total and released markers.
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Figure 11. Reproducibility relating to assay results for (a) total ECP, (b) total MPO. Geomet-
ric mean concentration for each subject is plotted against difference between day 1 and day 2, 
or the difference between log values. The solid line represents the line of identity. The broken 
lines (line of identity ± 2SD) represent the limits of agreement for the group as a whole.
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Table 19. Reproducibility of assay results relating to markers in sputum
                         Total marker R
i
         Released marker R
i 
ECP                           0.78                                0.85
EPO                           0.22                                0.52
HNL                          0.61¶                                0.91
MPO                          0.90                                0.97
R
i
 is the intraclass correlation coeffi cient ¶One outlier excluded
The reproducibility of differential cell counts was determined in relation to counts using 
10 cytocentrifuged preparations stained with MGG. Within-examiner (PR) reproducibi-
lity was high for all cell types (Table 20). Between-examiner (TM and PR) was poorer in 
respect of lymphocytes, macrophages and bronchial epithelial cells than within-examiner 
reproducibility.
Table 20. Reproducibility of differential cell counts in sputum
Cell type                                Within-examiner R  Between-examiners R  
                                                          n = 10 n = 10
Eosinophils                                          0.98 0.81
Neutrophils                                         0.93 0.86
Lymphocytes                                        0.89 0.34
Macrophages                                        0.92 0.44
Bronchial epithelial cells                      0.94 0.69
Squamous epithelial cells                     0.85 0.98
R = reliability coeffi cient
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6. DISCUSSION
6.1. Reliability of assay for total markers (Study I)
If a test is to be clinically useful it needs to be reliable. Reliability of a test can be deter-
mined by comparing test results with results obtained by objective means, e.g. in this case 
bronchial biopsy fi ndings. Reliability of the assay method studied can also be demonstra-
ted by showing that assay results can be used to distinguish between different types of 
infl ammation having different causes, and that assay results are responsive to changes in 
the clinical situation. In the studies reported here, assay results relating to sputum from 
healthy subjects, asthmatics, patients with respiratory infection and patients with COPD 
differed signifi cantly, regardless of the procedure followed. Concentrations of EPO and 
eosinophils in the sputum of patients with COPD and asthma were higher than in sputum 
from members of the other two groups. Concentrations of MPO and HNL and percentages 
of neutrophils in relation to other cells in sputum samples were also higher in patients 
with COPD and subjects with respiratory infection than in asthma patients or healthy 
subjects.
Pre-treatment ECP values in sputum from asthma patients were signifi cantly higher than 
in healthy subjects. However, the range of ECP levels in sputum was wide in both patients 
and healthy subjects, with overlap of values between groups. Sputum contains secretions 
from gland cells of the respiratory epithelium and submucosa, together with infl ammatory 
cells that have migrated from the bloodstream [70, 117]. Induced sputum also contains 
saliva, transudate and inhaled sodium chloride solution. The presence of any of the above-
mentioned factors could affect marker values in sputum. Good reproducibility of results 
of quantitative determinations of soluble total markers and cells in sputum samples from 
asthmatic patients has been reported by in’t Veen et al. [194]. ECP levels in saliva have 
been found to be no different in healthy subjects from those in asthmatics. The principal 
effect of saliva would therefore simply seem to be dilution of sputum [38]. In all except 
Study V results relating to sputum were not adjusted in relation to any biochemical or cel-
lular component because of a lack of a suitable alternate denominator in induced sputum. 
Sputum albumin concentrations, for example, are infl uenced not only by plasma-protein 
leakage but also by infl ammation.
In routine work, the simplest way of ensuring that a specimen is representative is to pre-
pare slides from untreated sputum, staining them with eosine-methylene blue and exa-
mining the slides under the microscope. We have used this approach even in health-care 
centres [172] and in connection with an epidemiological survey (T. Petäys, unpublished) 
and found it practical. The smears cannot be used for differential cell counting but propor-
tions of different cells can be assessed semi-quantitatively [65, 172]. Sputum processing 
to obtain cytospin slides and allow differential cell counting is laborious and suitable only 
for specialist centres.
The value of determining levels of biochemical markers in addition to counting infl am-
matory cells can be debated. Our aim was to develop a simple sputum-processing method 
that could be used even in primary health care. The advantage of determination of total-
marker levels rather than released-marker levels is that the former is simpler and takes less 
time. Induction of sputum production and collection of sputum plugs are similar in the 
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two methods, and need similar amounts of time and labour. Sputum supernatant and cytos-
pin slides must be prepared within two hours. However, for determination of total-marker 
levels portions of sputum collected can be frozen, and processed further, batchwise. Sputum 
ECP levels have been shown to be stable over periods of six to nine months when sputum 
samples were stored at –20°C [48]. Our method for determination of total marker levels has 
been shown to give results similar to those obtained using “traditional” methods. Known 
amounts of pure mediator were added just before assay in these experiments to demonstrate 
reliability of the method. It would have been preferable to have added them to sputum 
before processing but the non-homogeneous nature of sputum precluded this.
6.2. Immunocytochemical detection of intracellular 
       markers (Study II, unpublished)
Cytospins of induced sputum samples are suitable for immuno cytochemical staining. Cells 
can easily be stained with conventional diffusible stains, such as the May-Grünwald-
Giemsa. Immunostaining of intracellular structures with monoclonal antibodies requires 
fi xation and permeabilization of the cell membrane. Our main fi nding was that the orga-
nic solvents commonly used in immunocytochemistry are not suitable fi xatives in pro-
cedures for detection of the intracellular, low-molecular-weight proteins concerned. Treat-
ment with crosslinking (aldehyde-based) fi xatives alone resulted in incomplete penetration 
of antibodies into the interiors of cells. Best results were obtained using the commercial 
reagent Ortho Permeafi x (OPF) for fl ow cytometry. With this reagent, fi xation and per-
meabilization take place simultaneously.
Cell-surface antigens can be identifi ed using labelled antibodies, with no treatment or 
mild treatment, but large antibody molecules cannot penetrate intact cell membranes. The 
common type of IgG antibody has an arm-to-arm distance of 146 Å [78]. If intracellular 
antigens need to be located, cell membranes need to be rendered permeable. Fixatives can 
be placed in one or other of three categories: (1) organic solvents that fi x and render cell 
membranes permeable simultaneously, (2) aldehyde-based fi xatives that do not affect per-
meability, and (3) fi xatives that affect permeability and have been adapted from those used 
in fl ow cytometry.
According to the ERS Sputum Task Force, the recommended method for fi xing sputum 
cells for immunocytochemical studies is treatment with acetone/methanol (60/40) for 
seven minutes (unpublished data, personal communication P. Rytilä). However, the results 
of our studies indicate that when organic solvents are used as fi xatives, recognition of gra-
nulocytes is uncertain because nuclear staining is very weak. It has been suggested that 
nucleic acids are lost, and that phospholipids are not precipitated but extracted [79]. The 
latter would itself result in weak nuclear staining. The study by Jahnsen et al. [82] showed 
that results obtained using organic solvents were not reproducible, and staining effects 
were weak. Jahnsen et al. studied one antigen (ECP) and two antibodies to different epito-
pes (monoclonal antibodies EG2 and EG1). Our observations relate to several granulocyte 
markers of different molecular weights and are in accordance with fi ndings above. Positive 
signals were weak for HNL and ECP, weak to moderate for EPO, and moderate for MPO 
when fi xation was carried out using organic solvents. No positive granules were observed, 
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either because of antigen leakage resulting from incomplete fi xation or because of poor 
penetration of large antibody molecules into cells.
The possibilities of leakage and redistribution of antigens are supported by previous fi n-
dings of inadequate immobilization of proteins with use of organic solvents [82, 110, 
127]. Melan et al. [128] have suggested that antigens with molecular weights below 100 
kDa are extracted if cells are fi xed with organic solvents at low temperatures. Our results 
suggest that cells with small proteins tend to exhibit greatest losses of antigenicity. The 
molecular weight of ECP is 18 to 20 kDa, of HNL 40 kDa, of EPO 67 kDa, and of MPO 
over 118 kDa. It is therefore not surprising that these antigens generally were not pro-
perly revealed and cells were only weakly positive in samples fi xed with organic solvents 
at any temperature. The largest antigen MPO (molecular weight over 100 kDa) exhibited 
greatest immunoreactivity when fi xation was carried out using organic solvents. Jahnsen 
et al. [82] have suggested that the variable and weak staining observed is a consequence of 
insuffi cient fi xation and, consequently, leaching of antigen. Our results support this sug-
gestion.
Aldehyde-based fi xatives (e.g. formalin) do not fi x by coagulation but crosslink proteins 
through reaction with basic amino acids, and formation of chemically stable methylene 
bridges [80]. Structural preservation is good but steric hindrance often occurs, making 
them unsuitable in relation to many antigens. Two crosslinking fi xatives, formaldehyde (as 
formalin) and periodate-lysine-paraformaldehyde, were used in the studies reported here 
relating to detection of intracellular antigens. Results for all antibodies tested were simi-
lar with both of these fi xatives. Cell preservation was acceptable and nuclear staining was 
better with these fi xatives than when organic solvents were used for fi xing. Immunoreac-
tivity was moderate.
Two commercial reagents (IntraPrep, OPF) marketed for fi xation and permeabilization of 
cells in suspension in fl ow cytometry were studied. As far as we know, this was the fi rst 
time they have been used in relation to sputum-sample and BAL-fl uid cells. Modifi ca-
tions of the procedures were necessary since visualization in immunocytochemistry invol-
ves complicated multistep procedures, not direct labelling as in fl ow cytometry. According 
to information provided by the manufacturers, both products contain formaldehyde (as 
formalin) as fi xative, IntraPrep at a concentration of 5.5%, and OPF at a concentration of 
1.78%. Permeabilization is achieved using a saponin in IntraPrep, a detergent and dimet-
hylsulphoxide (DMSO) in OPF [41]. DMSO is known to interact non-specifi cally with 
phospholipid membranes. This leads to membrane stabilization, decreased fl uidity, and 
increased microviscosity and permeability of cell membranes [117, 118]. An important 
property of OPF is its ability to fi x and permeabilize cells in a single step for intracellular 
antigen detection. OPF also allows access to numerous intracellular compartments, inclu-
ding the nucleus, cytoplasmic organelles such as mitochondria, and cytoplasmic granules, 
in addition to cytoplasmic proteins [41]. The same treatment protocol was used for all 
antigens and antibodies, without optimization for each. When cells were treated with 
OPF, we observed better penetration and immunoreactivity, and results were more repro-
ducible than with IntraPrep, which did not allow complete penetration of eosinophil gra-
nules. OPF best met the criteria for a good method of location of intracellular antigens in 
induced sputum and BAL samples.
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6.3. Specifi city of markers of infl ammation (Study II)
Two monoclonal antibodies to ECP, EG1 and EG2, have been widely used to identify eosi-
nophils in tissues [130, 195]. In the original publication on these antibodies, it was sug-
gested that EG2 would identify activated eosinophils, EG1 all eosinophils irrespective of 
their activation stage [185]. EG2-positive eosinophils have been demonstrated in various 
allergic and other infl ammatory disorders in over 100 reported studies. The suggestion 
that activated eosinophils play an important role has been based on use of EG2 antibody 
as a marker for activated cells. In some respiratory diseases, such as COPD and bronchiec-
tasis, levels of ECP were found to be related to numbers of neutrophils or neutrophil mar-
kers, such as MPO, in the same body fl uid (F. Hargreave, personal communication). These 
observations have raised some doubts about the cellular specifi city of ECP [82, 83, 181].
EG2-antibody recognises an epitope of EPX (EDN), an eosinophil granule protein known 
also to be synthesized in small amounts by neutrophils [169, 181]. Both ECP and EPX 
have ribonuclease activity and share a 67% amino acid sequence homology [55]. To date 
no data have been published indicating that ECP is synthesized by neutrophils. It has 
been suggested that ECP is actively taken up by blood neutrophils and stored in the gra-
nules of these cells [195, 196]. At present, it is not known if uptake of ECP also occurs 
in tissues. It has been suggested that uptake takes place ex vivo, because of leakage of ECP 
from poorly fi xed cells in tissues (Sevéus L. et al., submitted). This could partly explain 
intracellular staining of neutrophils with anti-ECP antibodies.
Jahnsen et al. [82] have emphasized the importance of fi xation in relation to intensities and 
specifi cities when labelling granular proteins with antibodies. We found that the organic 
solvents often used as fi xatives in immunocytochemistry are unsuitable for detection of 
intracellular proteins of low molecular weight. In addition, if intracellular antigens are 
to be identifi ed using labelled antibodies, cell membranes need to be permeable and int-
racellular antigens need to be fi xed in situ. However, in addition to EG2-positive eosi-
nophils, we found EG2-positive neutrophils, regardless of the fi xation and permeabiliza-
tion method used. When several different ECP-specifi c monoclonal antibodies were used 
in a fl ow-cytometric study, signifi cant intracellular staining, increasing in intensity from 
lymphocytes, monocytes, basophils, neutrophils to eosinophils, was noted (Håkansson L 
et al., unpublished data). The anti-EPO antibodies stained only eosinophils. These results 
indicate that ECP and EG2 antibodies cannot be regarded as eosinophil-specifi c in relation 
to location of eosinophils.
We studied whether EPO might serve as a specifi c marker for eosinophils (Study II). EPO, 
released by IgE-mediated stimulus [191], has been shown to bind in vitro to neutrophil 
membranes by a specifi c receptor mechanism [214]. Some EPO-positive neutrophils might 
therefore be expected if such mechanisms operated in neutrophils in sputum samples and 
BAL fl uid. However, we found no EPO-positive staining in any neutrophil in sputum 
or BAL samples, even when using high concentrations of anti-EPO antibodies. There are 
several possible explanations for this lack of EPO positivity. Release of EPO has been 
detected in vitro, but might not occur in vivo. Healthy individuals normally have apopto-
tic or necrotic eosinophils rather than activated eosinophils. It is believed that activated 
but not apoptotic cells release their contents. The specifi c IgE stimulus may have been 
lacking in our subjects since only two patients were atopic to birch pollen, and samples 
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were obtained from them outside the pollen season. We therefore believe that EPO may 
be a specifi c marker for eosinophils.
Most neutrophil-derived markers are not specifi c to neutrophils. For example, MPO is also 
expressed by monocytes [203]. When anti-MPO antibodies were used as a primary anti-
body, all cells except neutrophils remained unstained. In one patient with asthma, mono-
cytes and neutrophils were positive for MPO antibodies in her sputum and BAL samples. 
Although monocytes themselves are seldom found in sputum or BAL samples, we wanted 
to fi nd an entirely neutrophil-specifi c marker in these sample materials. HNL was tested 
as a candidate. The cell specifi city of HNL had been investigated in lung-biopsy material 
and peripheral blood cells [178] but not in sputum samples or BAL fl uid. In a study by 
Nielsen et al. [137] very high expression of NGAL (neutrophil-gelatinase-associated lipo-
calin, identical to HNL) was seen in epithelial cells from infl amed colon, using polyclonal 
antibodies and in situ hybridization. A very weak signal was seen in healthy colonic epit-
helium. Ciliated epithelial cells in sputum samples and BAL fl uid were therefore carefully 
studied but no signs of HNL positivity were noted. This fi nding was in accordance with 
our previous fi ndings relating to intact lung tissue [178].
Macrophages positive for all antibodies studied were occasionally observed among sputum 
and BAL fl uid cells. This was not unexpected, as it has been shown in in vitro studies 
that apoptotic eosinophils are recognized and phagocytosed by macrophages [183]. Simi-
lar observations have been reported by Grigg et al. [63], who observed free and ingested 
apoptotic neutrophils in BAL-fl uid samples.
The ideal would be double staining of cells to identify eosinophils and neutrophils, but 
we did not try this. Since there is no consensus concerning the best way of fi xation, recog-
nition of immunolabelled cells was based on cell morphology. This approach was possible 
because characteristic leukocyte cell structures (bilobular versus multilobular nucleus, gra-
nules) were well preserved.
6.4. Sensitivity of sputum analysis (Studies III and IV)
The sensitivity of sputum ECP values in confi rming a diagnosis of asthma was 33% 
(patients with early or suspected asthma, Study III) to 35% (patients with newly detected 
mild asthma, Study IV). The diagnostic values of determination of sputum and serum 
ECP levels was judged by means of ROC curves. These allow visual expression of the diag-
nostic value of a test. Since judging diagnostic performance on the basis of a single cut-off 
value can be misleading, AUC is preferred. Here, the analysis revealed that determination 
of ECP levels in sputum (AUC = 0.78) was more sensitive than determination of ECP 
levels in serum (AUC = 0.63). In a study by Pizzichini et al. [155], similar but slightly 
higher values were reported for patients with more severe asthma (AUC for sputum ECP 
levels 0.80, for serum ECP levels 0.67). The lower sensitivity found in our studies is 
probably explained by patient selection. Our patients mostly had mild, newly detected 
asthma and did not enter the study during an active phase of the disease.
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6.5. Effect of treatment on markers of infl ammation 
       (Studies IV and V)
We observed signifi cant decreases in sputum ECP levels after inhaled steroid treatment, 
with parallel improvements in PEF, symptom scores and blood eosinophils, in both adults 
(Study IV) and children (Study V). No corresponding improvement was seen in adult 
patients treated with a β
2
-agonist. Two weeks of treatment with an inhaled steroid after 
β
2
-agonist therapy resulted in improvement similar to that seen in patients initially trea-
ted with an inhaled steroid. Levels of serum ECP before treatment were slightly but not 
signifi cantly higher in patients with early and mild asthma than in healthy subjects (p 
= 0.11). Serum ECP levels tended to decrease during treatment, and refl ected changes in 
blood eosinophil numbers.
The fi nding was expected since most pre-treatment serum ECP values already lay within 
the reference range (Study IV). In one patient with mild asthma and almost normal lung 
function (PD
15 
= 0.12 mg, FEV
1 
= 103.4%, PEF = 98%), a 35-fold decrease in sputum 
ECP level was observed during steroid treatment (baseline 35900 µg/L, after treatment 
1032 µg/L). Serum ECP level also decreased slightly (baseline 13.8 µg/L, after treatment 
5.0 µg/L) but remained throughout within the reference range. At baseline, the number 
of blood eosinophils (0.60 x 109/L) had been slightly high. In patients with prolonged 
and severe asthma, signifi cant decreases in serum ECP have been observed during anti-
infl ammatory treatment [158]. High serum ECP levels in newly detected asthma are usu-
ally observed only in patients with severe lung-function disturbance.
Cellular and biochemical analyses of induced sputum samples showed signifi cant differen-
ces between patient groups when two sputum-processing methods (relating to determina-
tion of levels of total and released markers) were compared. We also studied whether the 
two methods of analysis of induced sputum samples revealed similar reductions in mar-
kers of infl ammation during treatment. Fourteen patients with asthma were treated with 
inhaled steroid for three months, and sputum samples were assayed using both methods 
before and after therapy (unpublished data relating to a subgroup from the study reported 
in reference 171). Treatment with inhaled steroid was associated with signifi cant decrea-
ses in all eosinophilic markers but not in any neutrophilic marker, independently of the 
sputum-processing method used. The changes in sputum concentrations of total markers 
during steroid treatment are similar to those seen by other investigators, and when other 
methods have been used [27, 158]. Analysis of induced sputum samples using the method 
presented here could therefore be useful for study of the effects of treatment on airway 
infl ammation.
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7. SUMMARY
The population in Studies I to V consisted of 171 patients and 97 healthy controls. The 
patients were mainly outpatients of the Skin and Allergy Hospital (Helsinki University 
Central Hospital, Finland). The healthy subjects were recruited from staff of the Hospital 
and their relatives.
In Study I, the aim was to make studies of induced sputum samples more practicable by 
simplifying sample processing. Two methods of processing sputum were used. Levels of 
total and released markers for ECP, EPO, MPO and HNL were measured. Results obtained 
using different methods were compared and cell profi les were assessed. Correlations bet-
ween total and released marker concentrations were excellent for ECP and HNL, good for 
MPO and moderate for EPO when all study groups were evaluated. Correlations varied 
between study groups and markers. Levels of total and released ECP and EPO correlated 
signifi cantly with percentages of eosinophils when all study groups were included. Simi-
larly, total and released HNL and MPO levels correlated with percentages of neutrophils. 
Power of correlation depended, however, on study group and marker. For example, signi-
fi cant correlations between percentages of eosinophils and total ECP and EPO concentra-
tions were found in asthmatics but not in patients with COPD or healthy individuals. The 
reproducibilities of assays for markers of infl ammation and of differential cell counts were 
found acceptable.
In Study II, the aim was to investigate whether EPO and HNL could serve as more cell-
specifi c markers for eosinophils and neutrophils than the established markers ECP and 
MPO. Induced-sputum and BAL-fl uid samples were obtained from 14 patients with res-
piratory conditions and four healthy controls. Cells in the samples were fi xed using the 
optimal method for intracellular markers and immunolabelled with antibodies to eosino-
phil-derived (EPO, ECP) and neutrophil-derived (HNL, MPO) intracellular markers. Cell-
specifi city was studied. Anti-EPO antibodies reacted only with eosinophils and anti-HNL 
antibodies only with neutrophils. Anti-ECP antibodies reacted with both eosinophils and 
neutrophils, anti-MPO antibodies with both neutrophils and monocytes.
In Study III, the performances of various laboratory tests were examined in 23 patients 
who had exhibited symptoms suggestive of asthma for less than a year. A group with 
chronic asthma and healthy subjects served as reference populations. Lung-function tests 
were performed in both patient groups. Even in the best case (the histamine-challenge 
test) sensitivity was only 48% for patients with early or suspected asthma. When this test 
was supplemented with PEF determination sensitivity was 65%. After supplementation of 
these two tests with assay for sputum ECP levels sensitivity was 74%. After supplementa-
tion of these three tests with assay for serum ECP levels sensitivity was 78%. A combina-
tion of tests measuring lung function and activation of eosinophils gave only fair results. 
The sensitivity of assay for sputum ECP levels was higher in patients with chronic asthma 
(76%) than in patients with early or suspected asthma.
In Study IV, several lung-function and biochemical tests were carried out in relation to 
80 adult patients with early, mostly mild, asthma and 30 healthy subjects. Patients were 
randomly assigned to one or other of two treatment groups and treated for six weeks. 
Treatment with an inhaled steroid was found to be effective: symptom scores, PEF, blood 
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eosinophils and sputum ECP values all improved. Inhaled b
2
-agonist was ineffective in 
these respects. Determination of sputum ECP levels proved to be the best biochemical test 
for detection of early asthma and monitoring of treatment effects. However, the sensitivity 
was modest (33%) when untreated patients were examined.
In Study V, utility of determination of sputum and serum ECP levels was assessed in 14 
children with newly detected asthma, before and after treatment, and in 10 healthy cont-
rols. The patients were treated with an inhaled steroid at two dose levels for six months, 
and with inhaled nedocromil for the following six months. On entry of the subjects into 
the study, both sputum and serum ECP levels were higher in patients than in controls. 
The difference was greatest in relation to sputum. Signifi cant clinical improvement during 
treatment, as judged by FEV
1
, PEF and symptom scores, was accompanied by decreases in 
sputum ECP levels. Serum ECP levels did not change. Sputum ECP levels were normal at 
six months, suggesting asthmatic infl ammation was well controlled. Sputum ECP levels 
also correlated inversely with increases in FEV
1
 during the fi rst month of steroid treat-
ment.
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8. CONCLUSIONS
1. Sputum production can be safely induced in patients with respiratory disorders and 
healthy individuals through use of a low-output nebulizer. Use of a simplifi ed assay 
method for measuring levels of total granulocyte markers in sputum allows differentia-
tion between patients with respiratory disorders and healthy individuals. Determination 
of levels of total markers using the assay method gives results similar to those obtained 
through use of established assay methods for released markers. The results suggest that the 
assay method could be used in clinical practice to determine total marker levels in induced 
sputum samples.
2. EPO is an unique component of eosinophils and HNL is an unique component of neut-
rophils. EPO and HNL can be used as markers for identifi cation of eosinophils and neut-
rophils in sputum samples and bronchoalveolar lavage fl uid. The marker ECP, which is 
widely used, is not eosinophil-specifi c. It can be detected by means of immunocytoche-
mical methods in both eosinophils and neutrophils, irrespective of the fi xation method 
used. Fixation and permeabilization using the commercial reagent Ortho Permeafi x is best 
for detection of antigens in cells in sputum samples and BAL-fl uid. The recommended 
method of fi xation with an organic solvent is improper in this connection.
3. Detection of early or suspected asthma is diffi cult, since no suffi ciently sensitive method 
is available to confi rm or exclude the diagnosis. The sensitivity of a combination of lung-
function tests and measurements relating to sputum is substantially higher.
4. Treatment of early, mild asthma with an inhaled steroid is effective and worthwhile. 
Detection of the disease remains problematic, since both lung-function and biochemical 
tests have low sensitivities. Sputum assays are, however, a useful supplement to conventio-
nal lung-function testing.
5. The method for induction of sputum production studied can be used to monitor the 
effects of treatment also in children. Sputum ECP levels in children refl ect the local 
infl ammation in asthma better than serum ECP levels.
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